BRIGHT 2.0   Version 4.0  
Protocol #103191   1 October 2021  
 
 a A Single -Site, Parallel -Group, Randomized- Controlled 
Pi[INVESTIGATOR_516508] (BRIGHT 2.0)  
 
 
Protocol Number: 103191 
 
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED] 
 
Principal Investigator:  [INVESTIGATOR_516509], M .D., M.P.H. , FACS  
 
Sponsor: Hollings Cancer Center  
 
Grant Title: A Novel Treatment Strategy for Body Image Disturbance in Head and 
Neck Cancer Survivors  
 
Grant Number: R21CA245941 
 
Funded by: [CONTACT_516554]:  v.4 .0 (1 October , 2021)  
 
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669463].  
  
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669464] ORY 
 
Section 5.2 Exclusion Criteria : Removed “exclusion criteria ” of (1) recurrent/new primary cancer 
following trial registration and (2) major surgery following trial registration. These criteria were 
incorrectly listed as exclusion criteria even though their determination occurred after a patient was 
enrolled (and thus they cannot, by [CONTACT_108], be exclusion criteria).  
 Section 5.5  Strategies for Recruitment and Retention : Changed target accrual from [ADDRESS_669465] a higher than anticipated rate of patients discontinuing the study due to recurrent or second primary cancers ( Section 7.2 ). The evaluable sample size remains unchanged (N=44).  
 Section 7.2 Particip ant Discontinuation/Withdrawal from the Study:  Refined criteria for study 
discontinuation to clarify the difference between an exclusion criterion (which is determined at the time of study accrual) and criteria for study discontinuation (which are determined after a patient accrues to the study). The criteria (recurrence or second primary cancer; major head and neck surgery) and rationale (these events/.medical conditions are such that continued f/u of the patient in the study is not in the participant’s best interest and would confound interpretation of the study) remain the same but are now appropriately described as criteria for discontinuation instead of exclusion criteria.  
 Section 9.2 Sample Size Determination: Changed target accrual from [ADDRESS_669466] a 
higher than anticipated rate of patients discontinuing the study due to recurrent or second primary cancers ( Section 7.2 ). The evaluable sample size remains unchanged (N=44).  
 Section 9.3 Population for Analyses: Amended to reflect update s to eligible vs evaluable population as 
described in Sections 5.2  and 7.2  
 
Section 10.4 Protocol Amendment History:  Updated to reflect protocol revisions noted herein.  
  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 4 TABLE OF CONTENTS  
Table of Contents  
CONFIDENTIALITY STATEMENT ........................................................................................................................................ 2  
PROTOCOL VERSION HISTORY .......................................................................................................................................... 3  
TABLE OF CONTENTS  ........................................................................................................................................................ 4  
STATEMENT OF COM PLIANCE  .......................................................................................................................................... 7  
INVESTIGATOR’S SIGNATURE  ........................................................................................................................................... [ADDRESS_669467] of BRIGHT on HNC -Related Quality  of Life  ............................ 18 
2.3 Risk/Benefit Assessment  ........................................................................................................................ 19 
2.3.1 Known Potential Risks  ........................................................................................................ 19 
2.3.2 Known Potential Benefits  ................................................................................................... 19 
2.3.3 Assessment of Potential Risks and Benefits  ....................................................................... 19 
3 OBJECTIVES AND ENDPOINTS  ............................................................................................................................ 21 
4 STUD Y DESIGN  ................................................................................................................................................... 23 
4.1 Overall Design  ......................................................................................................................................... 23 
4.2 Scientific Rationale for Study Design ...................................................................................................... 24 
4.3 Justification for Intervention  .................................................................................................................. 24 
4.3.1 Justification for the Mode of Delivery  ................................................................................ 24 
4.3.2 Justification for the Nubmber, Frequency, and Timing of Intervention Contacts  ............ 24 
4.4 End- of-Study Definition  .......................................................................................................................... 25 
5 STUD Y POPULATION  .......................................................................................................................................... 25 
5.1 Inclusion Criteria  ..................................................................................................................................... 25 
5.2 Exclusion Criteria  .................................................................................................................................... 26 
5.3 Lifestyle Considerations  .......................................................................................................................... 26 
5.4 Screen Failures  ........................................................................................................................................ 26 
5.5 Strategies for Recruitment and Retention  ............................................................................................. 26 
5.5.1 Anticipated Screening and Accrual Targets  ....................................................................... 26 
5.5.2 Anticipated Accrual Rate and Accrual Feasibility  ............................................................... 27 
5.5.3 Planned Screening and Recruitment Strategies ................................................................. 28 
5.5.4 Strategies to Enhnace Retention  ........................................................................................ 28 
5.5.5 Retention Feasibility  ........................................................................................................... 29 
5.5.6 Participant Compensation  .................................................................................................. 29 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 5 6 STUDY INTERVENTION(S) OR EXPERIMENTAL MANIPULATION(S)  ................................................................... 29 
6.1 Study Intervention(s) or Experimental Manipulation(s) Administration  .............................................. 30 
6.1.1  Study Intervention Description  .......................................................................................... 30 
6.1.2 Administration and/or Dosing  ............................................................................................ [ADDRESS_669468] Training and Tracking  ................................................................................ 32 
6.3 Measures to Minimize Bias: Randomization and Blinding  .................................................................... 32 
6.4 Study Intervention Adherence  ............................................................................................................... 32 
6.4.1 BRIGHT  32 
6.4.2 AC 33 
6.5 Concomitant Therapy  ............................................................................................................................. 33 
6.5.1 Rescue Therapy  ................................................................................................................... 33 
7 STUDY INTE RVENTION DISCONTINUATION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL  ............. 33 
7.1 Discontinuation of Study Intervention/Experimental Manipul ation  .................................................... 33 
7.2 Participant Discontinuation/Withdrawal from the Study  ..................................................................... [ADDRESS_669469]  ................................................................................................... 40 
8.3.9 Reporting of Pregnancy  ...................................................................................................... 40 
8.4 Unanticipated Problems  ......................................................................................................................... 40 
8.4.1 Definition of Unanticipated Problems ................................................................................ 40 
8.4.2 Unanticipated Problems Reporting  .................................................................................... 40 
8.4.3 Reporting Unanticipated Problems to Participants  ........................................................... 41 
9 STATISTICAL CONSIDERATIONS  ......................................................................................................................... 41 
9.1 Statistical Hypotheses ............................................................................................................................. 41 
9.2 Sample Size Determination  .................................................................................................................... 41 
9.3 Populations for Analyses  ........................................................................................................................ 43 
9.4 Statistical Analyses .................................................................................................................................. 44 
9.4.1 General Approach  ............................................................................................................... 44 
9.4.2 Analysis of the Primary Endpoint(s)  ................................................................................... 44 
9.4.3 Analysis of the Secondary Endpoint(s)  ............................................................................... 44 
9.4.4 Safety Analyses  ................................................................................................................... 45 
9.4.5 Baseline Descriptive Statistics  ............................................................................................ 45 
9.4.6 Planned Interim Analyses  ................................................................................................... 46 
9.4.7 Sub-Group Analyses  ............................................................................................................ 46 
9.4.8 Tabulation of Individual Participant Data  .......................................................................... 46 
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669470] Policy .................................................................................................... 51 
10.2 Additional Considerations  ...................................................................................................................... 51 
10.3 Abbreviations and Special Terms  ........................................................................................................... 51 
10.4 Protocol Amendment History ................................................................................................................. 53 
11 REFERENCES  ....................................................................................................................................................... 54 
 
  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 7 STATEMENT OF COMPLIANC E 
The trial will be conducted in accordance with International Council on Harmonisation Good Clinical 
Practice (ICH GCP), applicable [LOCATION_002] (US) Code of Federal Regulations (CFR), and the National 
Cancer Institute (NCI) Terms and Conditions of Award. The Principal Investigator (PI) will assure that no deviation from, or changes to the  protocol will take place without prior agreement from the funding 
agency and documented approval from the Institutional Review Board (IRB), and the Investigational New Drug (IND) or Investigational Device Exemption (IDE) sponsor, if applicable, except whe re necessary to 
eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection and ICH GCP Training.  
 The protocol, informed consent form(s), recruitment materials, a nd all participant materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and the consent form(s) must 
be obtained before any participant is consented. Any amendment to the protocol will require review and 
approval by  [CONTACT_3484]. All changes to the consent form(s) 
will be IRB approved; a determination will be made regarding whether a new consent needs to be obtained from participants who provided consent, using a previously approved consent form.  
  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 8 
INVESTIGATOR’S SIGNA TURE  
The signature [CONTACT_516604], including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US 
federal regulations and ICH guidelines, as described in the Statement of Compliance  above . 
 
Principal Investigator [INVESTIGATOR_9095]:  
 
Signed:    
Date:   
3/10/20 
  
Name: [CONTACT_516605]: A Single -Site, Parallel -Group, Randomized -Controlled Pi[INVESTIGATOR_516510] (BRIGHT 2.0)  
 Investigator Contact [CONTACT_9121]: Medical University of South Carolina  
Address: [ADDRESS_669471], MSC 550, Charleston, SC [ZIP_CODE] Telephone: (843) -792- 0719 
Email: [EMAIL_9863]  
 CO-INVESTIGATORS:  
Stacey Maurer, PhD  
Wendy Balliet, PhD  
Hong Li , PhD  
Ken Ruggiero, PhD  
Katherine Sterba, PhD, MPH   
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 9 1 PROTOCOL SUMMARY  
1.1 SYNOPSIS  
 
Title:  A Single -Site, Parallel -Group, Randomized -Controlled Pi[INVESTIGATOR_516511] (BRIGHT 2.0)   
Grant Number:  R21CA245941   
Study Description:  In this pi[INVESTIGATOR_2269], we will evaluate the preliminary 
clinical impact and underlying behavioral mechanism of BRIGHT 
(Building a R enewed I maGe after H ead & neck cancer T reatment ), a 
novel  5-session, manualized cognitive behavioral therapy (CBT)  
intervention  to treat body image disturbance (BID) in head and neck 
cancer (HNC) survivors. We hypothesize that BRIGHT will decrease BID relative to act ive control ( AC; patient -centered videos about HNC 
survivorship care ) through improvements in body image copi[INVESTIGATOR_464555].  
 
Objectives:  Primary Objective:  
To assess the clinical efficacy of BRIGHT compared with AC on BID in HNC survivors as determined by [CONTACT_516555] (BIS) scores at 1-month post -intervention relative to baseline.  
 
Select S econdary Objectives:  
1. To assess the clinical efficacy of BRIGHT compared with AC on BID in HNC survivors as determined by [CONTACT_516556] -HN scores at 1- month 
post -intervention relative to baseline  
 2. To e xplore the behavioral mechanism of action of BRIGHT on changes 
in BID in HNC survivors as measured by [CONTACT_516557][INVESTIGATOR_503625] (BICSI) scores at [ADDRESS_669472] -
intervention relative to baseline.  
 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 10  
 
          
 
 Endpoints:  6. To evaluate the preliminary clinical efficacy of BRIGHT compared with 
AC on changes in psychological, emotional, and social well -being in HNC 
survivors at post -treatment and [ADDRESS_669473]  
 
Primary Endpoint:  
Change in BIS score from baseline to [ADDRESS_669474] Secondary Endpoints:  
1. Change in IMAGE -HN score from baseline to [ADDRESS_669475] -intervention  
 3. Clinical response (BIS score at [ADDRESS_669476] -intervention that is less 
than the BIS score at baseline)  
 4. Change in BIS score from baseline to [ADDRESS_669477] -intervention   
Study Population:  The study population will consist of head and neck cancer survivors with 
no evidence of disease, 18 years of age or older, of all races and sexes, 
with BID following treatment of HNC    
Phase or Stage:  N/A 
  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 11 Description of 
Sites/Facilities Enrolling 
Participants:  The study will be conducted, and participants enrolled, at a single site, 
the Medical University of South Carolina (MUSC) Hollings Cancer Center (HCC) Head and Neck Tumor Center. The Head and Neck Tumor Center is a high- volume, multidisciplinary center designed for unsurpassed clinical 
care and optimized for integration of research activities. The Head and Neck Tumor Center is a regional center of excellence for HNSCC clinical care.  
 
Description of Study 
Intervention/Experimental 
Manipulation:  BRIGHT is 5 sessions of weekly, 60 -minute, tablet -based, manualized 
individual tele -CBT targeting the behavioral and attitudinal components 
of HNC -related BID.   
Study Duration:  24 months   
Participant Duration:  4 months  
  
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669478] of BRIGHT on changes in BID and the role of body image copi[INVESTIGATOR_516512] a mediator of changes in BID. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 13 1.3 SCHEDULE OF ACTIVITIES  
 
Table 1. Schedule of Activities for BRIGHT and Active Control (5 weeks) and follow up (3 months)  
 
Pre Screen  
(-60 to 1)  
Visit 1  
Day 1a 
 
Visit 2  
Day 8 ± 14 
Visit 3  
Day 15 ±7  
Visit 4  
Day 22 ±7  
Visit 5  
Day 29 ±7  
Visit 6 
Day 36 ±7  
Visit 7 
Day 43 ±14  
Visit 8 
Day 64 ±14  
Visit 9 
Day 124 ±14 For Details, 
see section  
Informed Consent  
Review  Study  
Eligibilityb X           5 
Informed Consentc X           10.1.1  
Study Procedures  
Randomization   X          6.3 
Demographics   X          8.1 
Clinical and 
Oncologic History  X      
    8.1 
ASI-R  X          8.1 
Monitoring  
AS/SAE 
Assessment    X X X X X X X X  8.3 
Medication 
Assessment    X X X X X X X X  8.3 
Intervention Administration  
BRIGHT or AC    X X X X X     6.1 
Efficacy Evaluation  
Body Image Scaled X       X X X  8.1 
IMAGE -HNd  X      X X X  8.1 
PROM Assessments  
BICSId  X      X X X  8.1 
Shame and Stigma 
Scaled  X       X X  8.1 
PROMIS SF v1.0 -
Depression 8ad  X       X X  8.1 
PROMIS SF v1.0 -
Anxiety 8ad  X       X X  8.1 
PROMIS SF v2.0 -
Social Isolation 8ad  X     
  X X  8.1 
PROMIS SF  v2.0 - 
Social Roles 8ad  X       X X  8.1 
EORTC QLQ -HN35d  X       X X  8.1 
Other Evaluations  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 14   Intervention 
Fidelity    X X X X X     6.2 
Patient Adherence    X X X X X     6.4 
Program 
Evaluation         X    8.1 
WAI -SR    X   X     8.1 
a: Every effort should be made to minimize the time between randomization and starting treatment  
b: Eligibility assessed using information in the electronic medical record as well as a screening Body Image Scale  
c: Written informed consent and HIPAA must be obtained prior to performing and protocol -specific procedures, 
including baseline evaluations.  To optimize participant and researcher safety during the COVID -19 pandemic, 
informed consent may be obtained in person using a paper informed consent document or electronically using the 
eConse nt. 
d: Sites are encouraged to administer PROMs using a site -based electronic device. If that is not feasible, 
administration of PROMs using a paper -based format is also acceptable. Sites are encouraged to align PROM 
assessments with clinic visits to facil itate in -person collection. In situations in which in -person collection is not 
feasible, PROMs may be collected via mail or email at the study coordinator’s discretion. When possible. PROMs 
should be completed prior to any other study procedures (following  informed consent) and before clinic visits in 
which clinical information will be discussed to avoid biasing the patient’s responses to the questions. 
Acronyms:  AC, Active Control; AE, Adverse Event; ASI -R, Appearance Schemas Inventory -Revised; BICSI, Bo dy Image 
Copi[INVESTIGATOR_503625]; BRIGHT, B uilding a R enewed I maGe after H ead & neck cancer T reatment;  IMAGE -HN; 
Inventory to Measure and A ssess ima Ge disturbanc E-Head & Neck; SAE, Serious Adverse Event; WAI -SR, Working 
Alliance Inventory -Short Revised  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 15 2  INTRODUCTION  
2.1 STUDY R ATIONALE   
Head and neck cancer (HNC) arises in cosmetically and functionally critical areas, resulting in substantial 
life-altering morbidity related to disfigurement, difficulty swallowing, and challenges speaking1,2. As a 
result, 75% of HNC survivors express body image concerns3,4. When severe, these concerns result in body 
image disturbance (BID), a multidimensional construct characterized by a displeasing self -perceived 
change in appearance and/or function4-6. Although BID is a source of significant morbidity and ass ociated 
with stigmatization, social isolation, and decreased quality of life (QOL)7,8, effective therapi[INVESTIGATOR_516513]8. It is therefore critically important to develop and test novel interventions to 
minimize psychosocial morbidity and improve QOL in this population7,8. 
 
We have developed and pi[INVESTIGATOR_2268] -tested BRIGHT ( Building a R enewed ImaGe after H ead & neck cancer 
Treatment), a novel 5 -session, manualized cognitive behavioral therapy (CBT) interven tion to treat BID in 
HNC survivors. BRIGHT targets the behavioral and attitudinal components of BID and can be delivered 
face to face or using a tablet -based telemedicine format. In our single -arm pi[INVESTIGATOR_516514], 
participants were given the option t o select their delivery platform and overwhelmingly enrolled into 
tablet- based BRIGHT (n=10) instead of face to face BRIGHT (n=1). This pi[INVESTIGATOR_516515] -
based BRIGHT (n=10) is feasible (100% of sessions completed), is acceptable to patients ( 89% highly likely 
to recommend it), has the potential to decrease BID ( mean decrease of 4.[ADDRESS_669479] intervention (95% CI 1.55, 7.56), and may mediate a reduction in BID by [CONTACT_516558][INVESTIGATOR_172510] . 
 In this proposal, we extend our initial research with a pi[INVESTIGATOR_2269] (RCT) to examine the clinical impact and behavioral mechanistic underpi[INVESTIGATOR_516516]. This proposed project  will evaluate the preliminary clinical impact and behavioral mechanism of a novel 
psychobehavioral intervention delivered via a scalable, tablet -based telemedicine platform, thereby 
[CONTACT_516559] . HNC survivors with BID will be randomized 
to 5 -weeks of tablet -based BRIGHT or tablet -based active control (AC) (patient -centered videos about 
HNC survivorship care . Participants will complete the Body Image Scale (a validated measure of BID
9; 
primary endpoint ), the Body Image Copi[INVESTIGATOR_503625] ( a validated measure of body image 
copi[INVESTIGATOR_172510]10; behavioral mediator) and measures of psychological, social, and emotional well -being 
(secondary endpoints ) at baseline, [ADDRESS_669480] -intervention.  
 
2.2 BACKGROUN D 
2.2.1  PYSCHOSOCIAL MORBIDITY IN HEAD AN D NECK CANCER SURVIV ORS  
HNC, which arises in cosmetically and functionally critical areas (tongue, mandible, larynx, and neck) is diagnosed in 65,000 patients in the US annually
11. HNC results in life -altering morbidity related to 
disfigurement, difficulty swallowing, impaired smiling, and challenges speaking12. Because changes occur 
in highly visible, socially significant parts of th e body that are integral to self -conception, communication, 
and interpersonal relationships7,8,13, 75% of HNC survivors express body image concerns3,4. When severe, 
these concerns result in BID, a multidimensional construct characterized by a displeasing self -perceived 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 16 change in appearance and/or function6,7. Morbidity from BID includes social isolation14, stigmatization7, 
depression13,15, decreased intimacy16, and worse QOL7,8. Due to this psychosocial morbidity, survivors of 
HNC are [ADDRESS_669481] of cosmetic 
rehabilitation18 and skin camouflaging19 on BID in HNC survivors; neither intervention was effective at 
treating BID. As a result, treatment of BID in HNC survivors represents a significant unmet survivorship 
need20. It is thus critically important to address the lack of treatments for BID in HNC survivors to prevent 
continued psychosocial morbidity and decreased QOL8. 
 
2.2.[ADDRESS_669482] demonstrated the efficacy or mechanism of action of CBT for 
BID in HNC survivors8,25. 
2.2.4  CONTENT OF BRIGHT  
BRIGHT was developed using  an intervention mappi[INVESTIGATOR_120229]26. Our qualitative work with HNC 
survivors identified key domains of HNC -related BID which BRIGHT targets: personal dissatisfa ction with 
appearance, other -oriented appearance concerns, appearance concealment, distress with functional 
impairments, and social avoidance27. 
 
2.2.5  TELEMEDICINE DELIVER Y PLATFOR M  
Cancer survivors face unique access -to-care barriers for face to face psychosupportive care28. For HNC 
patients, travel burden (due to the regionalization of HNC care29,30) is a critical barrier to psychosupportive 
care and contributes to excess morbidity and mortality31,32. HNC survivors also face physical access 
barriers that prevent face to face CBT including fatigue and treatment toxicity. As a result, innovative approaches to deliver psychobehavioral  interventions to HNC survivors are needed
33,34. Telemedicine is a 
promising solution because it decreases travel burden35, increases a ccess to care36, and provides effective 
behavioral health interventions37 (including CBT28,38). 
 We assessed the feasibility of delivering BRIGHT via patient -owned technology. Although a majority of our 
population owned a video -enabled device (smart phone=83%, tablet=36%, computer=64%, none=6%) and 
had home internet access (88%), we elected to provide each participant with the same video platform (tablet) and internet connection (cellular -enabled Wi -Fi) to enhance the standardization and rigor of our 
approach.  
 
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669483] that telemedicine is the preferred strategy to deliver CBT interventions to HNC 
survivors with BID. When patients chose the delivery method of BRIGHT (face to face or tablet -based) in 
our single -arm trial, tablet -based BRIGHT was overwhelmingly preferred (100% of patients traveling >25 
miles (8/8); 67% (2/3) of patients traveling < 25 miles) because of travel considerations, convenience, and 
flexibility . 
 
2.2.6  FEASIBILITY AND ACCEPTABILITY OF  BRIGH T 
Feasibility and acceptability of BRIGHT was evaluated in a single -arm clinical trial (NC T03518671). 
BRIGHT was found to be highly feasible and acceptable to patients in terms of the timing, method of 
delivery, duration, and content of the intervention ( Table 2 ). 
 
         
 
             
2.2.[ADDRESS_669484] OF BRIGH T ON BID  
BRIGHT demonstrated high levels of clinical activity in this population  of HNC survivors with BID in our 
single -arm pi[INVESTIGATOR_4251]39. Eighty -nine percent of participants (8/9) experienced improvement in their BID at 
1-month post -BRIGHT relative to baseline, pre -treatmen t levels. The clinical effect of BRIGHT on BID was 
large ( Fig. 2 ); BRIGHT was associated with a mean decrease of 4.[ADDRESS_669485] intervention (95% CI 1.55, 7.56). This clinical effect on BID persisted at [ADDRESS_669486] -
BRIGH T relative to baseline (mean of the difference of BIS scores from baseline to [ADDRESS_669487] = 3.56; 
95% CI 1.15 to 5.96).  
  Table 2. BRIGHT Feasibility and Acceptability  
Feasibility   
BRIGHT session length (median; IQR), minutes  54; 5  
BRIGHT session completion, n (%)  45, 100  
Major technical issues during BRIGHT sessions, n (%)  0 (0)  
Minor technical issues during BRIGHT sessions, n (%)  5 (11.1)  
Tablet returned to study team after BRIGHT, n (%)  10 (100)  
Study dropout, n (%)  1 (10)  
 
Acceptability to Patients (Program Evaluation)  Mean (SD)  
How well did the timing  of the program work for you?  4.44 (0.73)  
How well did the method  of program delivery work?  4.67 (0.5)  
How well did the number of sessions  work for you?  4.56 (0.53)  
How relevant was the content  of each session?  4.56 (0.30)  
Session 1  4.11 (1.27)  
Session 2  4.44 (0.73)  
Session 3  4.56 (0.53)  
Session 4  4.89 (0.33)  
Session 5  4.78 (0.44)  
How likely are you to recommend  BRIGHT?  4.89 (0.33)  
#Scale 0 -5; higher scores indicate greater satisfaction.  
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669488] BRIGHT as measured by [CONTACT_516560] N35 (median trouble with social eating scores = 66.67, 45.83, and 25, at baseline, [ADDRESS_669489] -BRIGHT respectively; Fig. 3). BRIGHT was also associated with an improvement in the trouble 
with social contact [INVESTIGATOR_136] [ADDRESS_669490] 
subdomain of the EORTC QLQHN35  (median trouble with social contact [INVESTIGATOR_103835] = 40, 26.67, and 16.[ADDRESS_669491] -BRIGHT respectively). BRIGHT was not associated with improvements in 
depression, anxiety, or shame and stigma post -treatment relative to baseline.  
 
 
 
    
Fig. 2. A) Decrease in the severity of body image disturbance (as determined by [CONTACT_516561]) 
at 1-month post -BRIGHT relative to baseline; B) Decrease in the severity of body image disturbance (as 
determined by [CONTACT_516561]) at [ADDRESS_669492] -BRIGHT relative to baseline.  
Fig. 3. A) Decrease in difficulty with social eating (as determined by [CONTACT_26740] -H&N35 Trouble with 
Social Eating Subscale scores) at [ADDRESS_669493] -BRIGHT relative to baseline; B) Decrease in 
difficulty with social contact (as determined by [CONTACT_26740] -H&N35 Trouble with Social Contact [CONTACT_516562]) at [ADDRESS_669494] -BRIGHT relative to baseline  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 19 2.3 RISK/BENEFIT ASSESSM ENT  
2.3.1  KNOWN  POTENTIAL RISKS  
Overall, this research study poses no more than minimal risks to participants. The single -arm pi[INVESTIGATOR_516517] a minimal risk study that was approved by [CONTACT_516563] 
(45CFR46.110). No formal DSMB was required, although a Data and Safety Monitoring Plan ( DSMP ) with 
PI [INVESTIGATOR_32397] -based oversight was created. The main study procedures include completion of questionnaires, 
which are generally considered minimal risk. There are no physical, financial, legal, social, or cultural, risks to the study participants by [CONTACT_514746].  The primary risks of the study are 1) 
psychological/emotional distress and 2) breach of privacy/confidentiality.  
 
Psychological/emotional distress:  Subjects may experience adverse psychological reactions such as 
anxiety, depression, stress,  or distress as a result of discussing issues related to cancer, body image, 
stigmatization, isolation, copi[INVESTIGATOR_4262], or social support. These issues may occur during the completion of study questionnaires (baseline or post -treatment) or during the in tervention (BRIGHT or 
AC). However, based on our prior and ongoing research, we expect that low rates of participant distress and believe that this risk is minimal. Nevertheless, we do have a specific protocol should a participant become distressed as a re sult of participation in this study. The project coordinator and [CONTACT_516610], the 
study psycho -oncologist both have extensive experience dealing with this patient population and 
appropriate safeguards have been put in place during our pi[INVESTIGATOR_516518].  
 
Breach of privacy/confidentiality:  There is also a slight risk that confidential information about the 
participant may be accidentally disclosed as study participants may be asked to provide information considered c onfidential or private during study interviews. The likelihood of this risk is low as all the 
investigators have been involved in similar research in the past and have not experienced this problem before due to adequate safeguards.  
 
2.3.[ADDRESS_669495] a reduction in the severity of their BID as well as improvement in their psychological, social, and emotional well -being). However, although we hypothesize a direct benefit 
to participants in the BRIGHT arm (in terms of BID, psychological, social, and emotional well -being), it is 
unknown whether patients will experience a direct benefit.  Data generated from this proposal are 
expected to provide benefits to society by [CONTACT_516564] -behavioral 
interventions may help treat BID in cancer survivors. The study is also expected to have broad significance 
and therapeutic implications beyond BID through development of a novel platform to deliver a variety of psychobehavioral interventions to cancer survivors . 
 
2.3.3  ASSESSMENT OF POTENTIAL RISKS AND BENEFI TS 
The decision to participate in this research will be voluntary  and individuals may refuse to take part or 
choose to stop taking part at any time. Participants will also be encouraged to take their time when answering questions and may decline to answer any question at any time. If patients become upset talking 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 20 about their cancer and the barriers that they faced, they will be offered a referral to the HCC Behavioral 
Medicine program (which is covered by [CONTACT_516565]) or the HCC Social Worker who 
will offer links to other HCC and community resources  
 Measures to protect against psychological and emotional distress are described below. Participants will 
be reminded that the decision to initiate and/or continue participating in this research is voluntary. Participants will be informed from the outset that  they are free to terminate the assessments, procedures, 
or therapy sessions at any time and/or refrain from answering any questions that make them uncomfortable. The interviewers are trained researchers who are experienced in the conduct of interviews rel ated to psychosocial aspects of cancer. Our past experience using these study measures 
suggest that data collection using these instruments can be conducted without undue psychological distress or exacerbation of symptoms among this population (HNC survivo rs with body image concerns). 
The study participant will be encouraged to take time when answering questions and may refuse to answer any question at any time during the study.  
 If at any point during the assessment, treatment, or follow -up period, subject s are in need of medical 
management, psychiatric consultation, or psychiatric hospi[INVESTIGATOR_059], they will be evaluated, and referral or treatment will be provided as indicated. If a subject becomes suicidal, emergency psychiatric assessment will be arranged. The subject will be closely monitored clinically until he/she is no longer suicidal, or an appropriate care plan is in place.  
 If a participant has a psychological adverse event filling out a questionnaire, the program coordinator will immediately contact [INVESTIGATOR_124]. Maurer, a licensed clinical psychologist and the designated study psycho -
oncologist, to immediately asses the subject and determ ine the appropriate course of action. In the event 
that [CONTACT_516610] is not available, a fellow licensed psychologist who works in the HCC Behavioral Medicine program will be contact[INVESTIGATOR_530]. Immediate backup and support will be available.  In situations in which suicidal 
ideation (or other psychiatric emergency) is endorsed during completion of study instruments and [CONTACT_516610] or immediate backup is not available, patients will be referred to the emergency room for immediate psychiatric assessment.  
 Standard safeguards are also in place in case an adverse psychological reaction occurs during a BRIGHT (or AC) telemedicine session. These include determination of the appropriateness of the participant for home -based telemental health care, determination of the adequacy  of infrastructure and technology, site 
assessments and procedures (obtaining patient’s address and local 9 -1-1/Emergency medical service 
provider; local provider contact [CONTACT_3031], alternate patient and emergency contact [CONTACT_3031]), and monitoring of risk during treatment (symptom levels, self -harm ideation, intention to harm others, 
changes in setting/patient situation) as described in the DSMP.  
 All cases of possible psychological distress noted by [CONTACT_516566]. In situa tions 
in which a participant has psychological distress from participation in the study of which the study team is not aware, participants will be encouraged to notify the PI [INVESTIGATOR_173003]. These adverse events will be reported directly to the IRB per protocol.  If project staff believe that a subject is distressed by [CONTACT_516567], the PI [INVESTIGATOR_516519].  
 To help ensure and protect privacy of participants and confidentiality of research data for the study, we will assign a unique study ID number to each subject’s information in place of his/her name [CONTACT_516606]. A ll hard copy and electronic files will be stored appropriately 
using double -locked methods and password- protection. Only the study team members will have access 
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669496] -protecte d 
electronic data capture format (REDCap) or paper -based forms depending upon patient preference. For 
the paper collection data method, the data collection form will be labeled only with the participant's 
unique study ID number, and then stored within lock ed drawers in a locked office. The information on 
these paper forms will be transferred to a password -protected REDCap database. Any exported data for 
analysis will be de -identified with all privately identifiable information automatically removed. The key  
linking subject ID number to an individual will be stored in the password protected REDCap database. The audio recordings from the qualitative interviews will be labeled only with the patient’s unique study ID and stored using password- protected files onl y accessible by [CONTACT_516568] -protected 
servers. Once data have been collected, only de- identified data will be exported for analysis. All study 
personnel will participate in training on protecting the privacy of study participants and pe rsonal 
information will not be disclosed to anyone outside of the research team. Only the principal investigator 
[INVESTIGATOR_516520]. We have no plan to 
use laptops, jump drives, CDs/DVD s to transport data.  
 On the whole, given the minimal risks to the study participants and the potential benefit of the research to participants and society, we believe that the potential reward to participants and society substantially outweighs the risks to the participants.  
 
[ADDRESS_669497] -
intervention  
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669498] -intervention  relative to 
baseline  Clinical  response (BIS score at [ADDRESS_669499] -intervention that is 
less than the BIS score at baseline ) 
To assess the clinical efficacy of 
BRIGHT compared with AC on BID in HNC survivors as determined by [CONTACT_516569]  3-months 
post -intervention  relative to 
baseline  Change in BIS score from baseline to 3- months post -
intervention  
To evaluate the preliminary clinical 
efficacy of BRIGHT compared with 
AC on changes in psychological, 
emotional, and social well -being in 
HNC survivors as determined by [CONTACT_516570] 1- and [ADDRESS_669500] intervention  
Feasibility  
To evaluate the feasibility of 
BRIGHT, delivered via a tablet -based 
telemedicine, as a strategy to treat BID in HNC survivors  Intervention s ession duration  (minutes)  
Intervention session completion rate  
Number of technical issues  with tablet platform  
Return of study -issued t ablet 
Study dropout  
Acceptability  
To evaluate the acceptability of 
BRIGHT to as a strategy to treat BID in HNC survivors Timing of Intervention (0 -5 Likert scale)  
Method of Intervention delivery (0 -5 Likert scale)  
# of Intervention sessions (0 -5 Likert scale)  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 23 Table 3. Study Objectives and Endpoints  
OBJECTIVES  ENDPOINTS  
Intervention content relevance (0 -5 Likert scale)  
Overall satisfaction with the Intervention (0 -5 Likert scale)  
Likelihood of recommending the Intervention (0 -5 Likert scale)  
To determine the association of 
demographic variables with 
therapeutic alliance between the 
study participant and psychologist  Age, race, sex, Working Alliance Inventory - Short Revised score  
Acronyms: AC, Active Control; ASI -R, Appearance Schemas Inventory -Revised; BICSI, Body Image Copi[INVESTIGATOR_516521]; BID, Body Image Disturbance; BIS, Body Image Scale; BRIGHT, B uilding a R enewed 
ImaGe after Head & neck cancer T reatment; HNC; Head and Neck Cancer, IMAGE -HN; I nventory to 
Measure and A ssess ima Ge disturbanc E-Head & N eck; WAI -SR, Working Alliance Inventory -Short 
Revised  
 
[ADDRESS_669501] the following hypotheses: 1) 
BRIGHT will result in a less severe BID relative to AC (primary objective) and 2) Improvements in body image copi[INVESTIGATOR_516522] [ADDRESS_669502], participants will be allocated to the two study arms (BRIGHT or AC) as follows. Upon 
enrollment and completion of the baseline assessments, patients will be randomized 1:[ADDRESS_669503], BRIGHT will be compared with AC. AC is educational information about HNC survivorship 
developed (with permission) using resources from the NCI, American Head & Neck Society, Thyroid Head 
and Neck Cancer Foundation (THANC), and MUSC. AC consists of 5 weekly 30 -minute sessions and is 
delivered one- on-one via a tablet -based telemedicine platform. AC replicates the number of sessions (5) , 
frequency (weekly), and delivery method of BRIGHT (tablet- based telemedicine platform) but differs in 
content to isolate the ‘active’ ingredient in BRIGHT. AC was originally matched to BRIGHT for session duration (60 minutes) but was decreased to 30 minutes/session based on feedback during pi[INVESTIGATOR_516523]. 
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669504] 
size and sample size of the BRIGHT intervention relative to AC in preparation for the definitive phase III 
RCT42. 
 An alternative approach is to compare BRIGHT to UC instead of AC. UC for HNC survivors with BID is educational material provided by [CONTACT_516571]
7. Comparison to AC is a 
strength of our approach because  AC is matched by [CONTACT_24109], frequency, number, and delivery method 
and delivered using the same tablet platform as BRIGHT. The matching of dose and delivery format between BRIGHT and AC allows us to isolate the role of BRIGHT content in treating BID as opposed to other factors that might confound an association between BRIGHT and improvements in BID were BRIGHT 
compared with UC (e.g. receipt of the tablet, additional  contact [CONTACT_516572]) . 
 
4.3 JUSTIFICATION FOR INTERVENTIO N 
4.3.1  JUSTIFICATION FOR TH E MODE OF DELIVER Y 
Cancer survivors face unique access -to-care barriers for face to face psychosupportive care28. For HNC 
patients, travel burden (due to the regionalization of HNC care29,30) is a critical barrier to psychosupportive 
care and contributes to excess morbidity and mortality31,32. HNC survivors also face physical access 
barriers that prevent face to face CBT including fatigue and treatment toxicity. As a result, innovative approaches to deliver psychobehavioral interventions to HNC survivors are needed
33,34. Telemedicine is a 
promising solution because it decreases travel burden35, increases access to care36, and provides effective 
behavioral health interventions37 (including CBT28,38). 
 We assessed the feasibility of delivering BRIGHT via patient -owned technology. Although a majority of our 
population owned a video -enabled device (smart phone=83%, tablet=36%, computer=64%, none=6%) and 
had home internet access (88%), we elected to provide each participant with the same video platform (tablet) and internet connection (cellular -enabled Wi -Fi) to enhance the standardization and rigor of our 
approach.  
 
Our pi[INVESTIGATOR_516524] d eliver CBT interventions to HNC 
survivors with BID. When patients chose the delivery method of BRIGHT (face to face or tablet -based) in 
our single -arm trial, tablet -based BRIGHT was overwhelmingly preferred (100% of patients traveling >25 
miles (8/8); 67% (2/3) of patients traveling < 25 miles) because of travel considerations, convenience, and 
flexibility.  
 
4.3.2  JUSTIFICATION FOR TH E NUBMBER, FREQUENCY , AND TIMING OF INTE RVENTION 
CONTACTS  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 25 A needs assessment conducted within our prospective cohort study of BID i n HNC survivors43 informed 
the timing (immediately after HNC treatment), setting (one -one psychotherapy), and delivery method 
(telemedicine or face to face) of BRIGHT.  These facets of BRIGHT delivery were subsequently confirmed 
in our single -arm pi[INVESTIGATOR_516525] ( Table 4 ) 
 
 
 
                  
4.[ADDRESS_669505] meet all of the following criteria:  
 
1. Age > 18 years at the time of screening  
2. History of pathologically confirmed invasive SCC (or histologic variant) of the upper aerodigestive tract ( oral cavity, pharynx , larynx, nose/ paranasal sinuses ), carcinoma of a major 
or minor salivary gland, or cutaneous malig nancy of the face or neck  
3. History of curative intent surgery with or without adjuvant therapy , with or without 
reconstruction  Table 4. Acceptability of Timing, Frequency, Duration, and Content of BRIGHT 
from the  Single- Arm Pi[INVESTIGATOR_4238] (n=9)  
Acceptability to Patients  Mean (SD)  
How well did the timing  of the program work for you?  4.44 (0.73)  
How well did the method  of program delivery work?  4.67 (0.5)  
How well did the number of sessions  work for you?  4.56 (0.53)  
How relevant was the content  of each session?  4.56 (0.30)  
Session 1  4.11 (1.27)  
Session 2  4.44 (0.73)  
Session 3  4.56 (0.53)  
Session 4  4.89 (0.33)  
Session 5  4.78 (0.44)  
How likely are you to recommend  BRIGHT?  4.89 (0.33)  
#Scale 0 -5; higher scores indicate greater satisfaction.  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 26 4. American Joint Committee on Cancer (AJCC) 8th Edition pathologic stage groupi[INVESTIGATOR_007] I- IV 
5. Completion of oncologic treatment within 12 months of study enrollment  (but no sooner than [ADDRESS_669506] -treatment completion ) 
6. No planned significant HNC ablative or reconstructive surger y (defined  by a postoperative 
inpatient stay of at least three days) during the study intervention or follow -up period  as 
determined by [CONTACT_516573]  
7. Willingness to be randomized to either BRIGHT or AC  
8. BIS score > 10  
 
5.2 EXCLUSION CRITERIA  
Participants who meet any of the following criteria are not eligible to participate in the study:  
1. Inability to speak or write English  
2. Pre-existing, ongoing CBT services for other disorders and the participant is not willing to 
discontinue the prior therapy for the duration of the proposed trial.  
3. Initiation or adjustment ( < 3 months of baseline) of psychotropic medication . 
4. Severe psychiatric comorbidity (e.g. suicidal ideation, psychosis)  
o The rationale for excluding these patients is that the study protocol may be 
therapeutically insufficient.  
 
5.3 LIFESTYLE CONSIDERAT IONS  
N/A 
 
5.4 SCREEN FAILURES  
Screen failures are defined as participants who consent to participate in this study  but are not 
subsequently assigned to the study intervention or entered in the study. Individuals who do not meet the criteria for participation in this trial (screen failure) because of meeting one or more exclusion criteria will 
not be rescreened.  
   
5.[ADDRESS_669507] 44 analytic subjects complete the study . The  
planned accrual stratified by [CONTACT_547], race, and ethnicity is shown in Table 5. Individuals across the lifespan 
will be included with the following exception: children (i.e., individuals under age 18) wi ll be excluded. 
Children are not eligible to participate in the study for the following scientific reasons: 1) HNC is a rare pediatric malignancy 2) the experiences of children with BID are different from those of adults. There is no maximum age to participate in the study. The investigative team has expertise working with adult HNC survivors across a large age range (19 -89 years) in prior research. The Head and Neck Tumor Center, where 
clinic -based recruitment and enrollment will occur, has appropriate facilities to accommodate individuals 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 27 in the included age range. Age will be collected, and data will be disaggregated by [CONTACT_516574] a biological variable during data analysis.  The age distribution included in the study 
(all ages > 18) will allow us to evaluate the impact of age on the feasibility, acceptability, and clinical impact 
of our study  intervention.  
 The planned distribution of subjects by [CONTACT_516575] 50% female and 50% male. The sex distribution for patie nts is expected to reflect the demographics of our target population ( HNC survivors 
with BID following surgery at the Medical University of South Carolina [MUSC]) based on our pi[INVESTIGATOR_10299]. There  are no specific outreach programs for recruiting based on sex.  Subjects will not be excluded from 
this study based on sex. Sex will be collected, and data will be disaggregated by [CONTACT_516576] a biological variable during data analysis.  
 
Patients of all races and ethnicities will be recruite d for the study in proportion to their existence in the 
study population (HNC survivors with BID following surgery at MUSC ). The planned distribution of subjects 
by [CONTACT_6270] -identified race in the trial is 78% white, 19% African American and 3% other.  The rati onale for the 
selection of racial proportions in the study is that race is not a known risk factor for BID. The planned 
distribution of subjects by [CONTACT_6270] -identified ethnicity in the trial is 97% non -Hispanic and 3% Hispanic. The 
rationale for the selection of ethnic proportions in the study is that ethnicity is not a known risk factor for BID. Race will be collected, and data will be disaggregated by [CONTACT_516577] a 
biological variable during data analysis.  
 
Table 5. Planned Recruitment by [CONTACT_4323], Ethnicity, and Gender  
 Ethnic Categories  
Racial 
Categories  Not Hispanic or Latino  Hispanic or Latino  Total  
Female  Male  Female  Male  
White  [ADDRESS_669508] 
44 analytic subjects complete the study . This accrual rate includes a 2 0% attrition due to study 
withdrawal  or development of a clinical event that makes the patient non -evaluable. These estimates 
are based on pi[INVESTIGATOR_516526] -arm pi[INVESTIGATOR_516525] . There are no specific accrual targets 
based on patient characteristics (sex, age, racial/ ethnic group).  For the proposed study, we predict an 
accrual rate of 2.3 subjects/month. We expect a slightly higher rate of accrual for the proposed trial because we have refined and optimized our recruitment strategies and SOP based on valuable lessons related to logistics, timing, and methods of screening that we learned while recruiting for the single -arm 
trial of BRIGHT. Although we would expect an even higher rate of accrual (e.g. 2.5 subjects/month) simply based on improvements that we have made whil e optimizing the SOP for recruitment, our 
proposed accrual rate is tempered slightly by [CONTACT_516578]. Although our single -arm pi[INVESTIGATOR_516527] a Body Image Scale 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 28 score >1, we refined our inclusion criteria for the proposed study to use a Body Image Scale score of > 
10 (a clinically relevant threshold), to allow us to target our intervention  more precisely and enhance 
our ability to evaluate mediation. The revised inclusion criterion is expected to impact recruitment minimally; 91% of patients who accrued to BRIGHT in our pi[INVESTIGATOR_516528].  Accrual for the single -arm pi[INVESTIGATOR_516529] 2.2 subjects/month. For the proposed study,  we 
predict an accrual rate of 2.3 subjects/month based on the fact that although we improved our accrual strategy based on our pi[INVESTIGATOR_20732], we will exclude 10% of previously eligible subjects because of more stringent inclusion criteria. Accruing 2.3 subje cts/month, we would reach our goal (n=44) in [ADDRESS_669509] (EMR) for the Head and Neck 
Tumor Center clinical schedule  in collaboration with the HNC clinical team . To screen for study eligibility, 
the research staff will use the EMR to review clinic schedules for new or returning patients with an 
appointment who are potentially eligible for the study. These appointments will include both in -person 
clinic visits to the MUSC Head and Neck Tumor Center or a telemedicine visit with a head and neck oncology provider.  Clinic rosters will be reviewed at a minimum of once per week, or more frequently if 
indicated by [CONTACT_516579].  As such, screening will generally be performed within [ADDRESS_669510] comparing BRIGHT with  AC using a “ clinic”- based 
approach, recognizing that in the era of COVID -19, “clinic” now consists of a combination of in -person and 
telemedicine visits. In-person r ecruitment will occur at the Head and Neck Tumor Center of the MUSC 
NCI- designated Hollings Cancer Center  and telemedicine -based recruitment will occur electronically 
during the telemedicine visit with the head and neck oncology provider that is happening in lieu of the in -
person visit . Recruitment for the study will occur using the tested, structured standard operating 
procedures  (SOPs) developed and optimized during our single -arm pi[INVESTIGATOR_516530]- based recruitment . This protocol was initially based on 
structured recruitment protocols from the PI (Evan Graboyes, MD , MPH, FACS ) and co -investigator 
(Katherine Sterba, PhD, MPH) that were previously successf ully employed for clinic -based recruitment of 
HNC survivors into psychobehavioral studies. The original recruitment SOPs  have been optimized based 
on our experiences in the pi[INVESTIGATOR_516531] c-
based screening, enrollment, and distribution of the tablet -based platform for BRIGHT delivery. Our 
experience recruiting for the single- arm study of BRIGHT also demonstrated that the active clinical 
practice of the PI [INVESTIGATOR_516532] a key factor in maximizing recruitment. The study participants may include patients of the PI’s, but will not be exclusively patients of the PI. Other than the notification of the study by [CONTACT_516580], the research team will not ask other HNC clinicians to be directly involved in recruitment. All of the recruitment will be handled by [CONTACT_516581].  
 
5.5.4  STRATEGIES TO ENHNAC E RETENTIO N 
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669511], we maintain active communication with 
participants during the study including prior to and between visits via each patient’s preferred mode of 
contact (e.g. text message, phone call, e -mail). I n addition, our pi[INVESTIGATOR_516533] a reminder message 1 -day prior to a scheduled BRIGHT 
session helped ensure low rates of missed sessions and high rates of retention. Second, BRIGHT was designed using a patient -centered needs assessment approach to ensure that the timing (immediately 
after HNC treatment), format (one -one psychotherapy), and delivery method (telemedicine) would 
ensure design of a feasible and acceptable intervention. While the  content of BRIGHT will not be active to 
the patients in the AC arm, the timing and delivery method are the same in both arms of the trial and will thus likely facilitate retention in the AC as well as the BRIGHT arm.  Third, we have accounted for the 
burde n of questionnaires while patients are recovering from treatment to ensure that the expected time 
survey -related time commitment is reasonable. Collection of questionnaires has been optimized in our 
pi[INVESTIGATOR_516534]. 
Fourth, participant retention is maximized through up -front careful screening and a thorough informed 
consent process to ensure that participants capable of, and interested in, participating in a clinical tr ial 
enroll.  
 
5.5.5  RETENTION FEASIBILIT Y 
Our pi[INVESTIGATOR_516535] -arm clinical trial of BRIGHT showed that retention for our study is highly feasible ( 90%; 
9/10 participants). The only participant who dropped out was the first participant enrolled in the study. 
This par ticipant had multiply recurrent HNC and decided, after the first session of BRIGHT, that she had 
more significant, concurrent competing demands and thus the BRIGHT program was not applicable to her most pressing concerns. Although challenges with retention  for cancer studies due to mortality (overall 
and disease -specific) and treatment toxicity are potentially problematic, our pi[INVESTIGATOR_516536]. We have also developed exclu sion criteria to minimize potential dropout. These include excluding potential participants with:  
1. High likelihood of requiring significant HNC surgery during the study period  
2. Pre-existing, ongoing CBT services for other disorders  
3. Current suicidal or homicidal ideation  
These strategies will ensure that retention is feasible, thus ensuring that given our feasible enrollment targets, the study remains appropriately powered.  
 
5.5.6  PARTICIPANT COMPENSA TION  
We strive to reinforce participants appropriately for a ttending visits and completing study procedures. 
Remuneration also occurs on a schedule that provides significantly more compensation at the end of the study time period. In the proposed study, participants will receive up to $125 : $25 for enrolling, $50 f or 
the intervention, and $50 for the follow -up questionnaires.  Participants will be compensated by [CONTACT_9434].  
This level of compensation is viewed as appropriate for the time of the patient and not unduly coercive.  
 
6 STUDY INTERVENTION(S ) OR EXPERIMENTAL MANIPULATION(S)  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 30 6.1 STUDY INTERVENTION (S) OR EXPERIMENTAL MANI PULATION(S)  ADMINISTRATIO N 
6.1.1  STUDY INTERVENTION D ESCRIPTIO N 
[IP_ADDRESS]  BRIGHT  
 BRIGHT is 5 sessions of weekly, 60 -minute, tablet -based, manualized individual tele -CBT targeting the 
behavioral, attitudinal, and cognitive components of HNC -related BID. The therapy manual and 
accompanying patient workbook include agendas for each sessio n, the theoretical and clinical rationale 
supporting the content, homework, 
and policies for tardiness, attrition, and homework noncompliance. BRIGHT focuses on adjustment to disfigurement, teaches copi[INVESTIGATOR_622] -solving skills, and addresses 
the behav ioral implications of BID. 
BRIGHT addresses the key conceptual domains of HNC -related BID ( Table 
6)
27.  BRIGHT session topi[INVESTIGATOR_604] 7 .  
 
[IP_ADDRESS]  AC 
AC is educational information about HNC survivorship developed (with permission) using resources from the NCI, American Head & Neck Society, Thyroid H ead and N eck C ancer Foundation (THANC), and MUSC . 
AC consists of 5 weekly 30 -minute sessions and is delivered one -on-one via a tablet -based telemedicine  
platform. The 5 sessions include  of AC are shown in Table 8. AC was p ilot tested with HNC survivors and 
refined based on their feedback to ensure its feasibility, appropriateness, and relevance.  
 
 Table 6. Domains of HNC -Related BID Targeted by [INVESTIGATOR_516551]27 
Domains  
Personal dissatisfaction with appearance  
Other-oriented appearance concerns  
Appearance concealment  
Distress with functional impairments  
Social avoidance  
Table 7. BRIGHT Session Topi[INVESTIGATOR_516537] #                                        Content  
1 Introduction to BRIGHT and setting goals for treatment  
2 Cognitive behavioral model for body image disturbance  
3 Cognitive restructuring – “talking back” to thoughts  
4 Avoidance  behaviors, safety behaviors , and social support  
5 Identifying personal values and thinking ahead  
Table 8. AC Session Topi[INVESTIGATOR_516537] #                                        Content  
1 HNC survivorship  
2 HNC physical late and long -term treatment toxicity  
3 HNC psychosocial late and long -term treatment toxicity  
4 Health maintenance  
5 Financial toxicity and return -to-work  after HNC  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 31 6.1.2  ADMINISTRATION  AND/OR DOSIN G 
Both BRIGHT and AC will be delivered using the same tablet -based telemedicine delivery platform. Upon 
enrollment, subjects in each arm receive, and are trained to use, a study -issued, Wi -Fi and 4GLTE cellular -
enabled iPads (32 Gb, 9.7 -inch screen with LED retina display, 1.2 MP front -facing camera with 780 p 
video -resolution). Each iPad is locked to prevent downloading of additional applications and pre -loaded 
with a SIM Card to enable cellular communication. Cellular service is provided by [CONTACT_516582] (99.86% 
coverage of South Carolina). The iPad is preloaded with Vidyo, a HIPAA -compliant, video teleconference 
platform. Vidyo allows face to face communication, but also includes a within -video text feature for 
aphonic (due to surgical removal of their larynx) or  severely dysarthric (due to surgical removal of their 
tongue) HNC patients. Subjects receive a hands -on tutorial about how to use Vidyo upon enrollment and 
a supplemental pi[INVESTIGATOR_516538]. To log into a session, the su bject 
clicks on the Vidyo application to enter the pre -assigned teleconference room and connect to the study 
psychologist (BRIGHT) or electronic information (AC). No user names, logins, or URLs are necessary. At the conclusion of the 5 -week intervention, s ubjects return the iPads to the study team in pre -addressed, 
stamped, padded mailers.  
 
[IP_ADDRESS]  BRIGH T 
BRIGHT will be delivered in one -on-one, face -to-face sessions between the study psychologist and 
participant using a tablet -based telemedicine platform . The BRIGHT intervention consists of five sessions 
of weekly, 60- minute, tablet -based, manualized individual tele -CBT ( see Section 1.3 , Schedule of 
Activities ). BRIGHT will be delivered by [CONTACT_516583] ( Stacey Maurer, PhD an d Wendy Balliet, PhD) . The use of two psychologists to deliver BRIGHT will 
enhance rigor and external validity and minimize confounding between the experimental intervention and interve ntionist.  Based upon our pi[INVESTIGATOR_20732], a full -dose of the intervention consists of five sessions 
within a six -week span with a mean session -length of [ADDRESS_669512] with other participants after randomization, regardless of treatment allocation. Such encounters may occur in waiting rooms before or after clinic appointments given the single -site design of the trial. Such encounters may also occur in the virtual and social network 
space through patient support forums and online communities of HNC survivors.  
[IP_ADDRESS]  AC 
AC consists of 5 weekly 30 -minute sessions and is delivered one -on-one vi a a tablet -based telemedicine 
platform. AC replicates the number of sessions (5), frequency (weekly), and delivery method of BRIGHT 
(tablet -based telemedicine platform) but differs in content to isolate the ‘active’ ingredient in BRIGHT (see 
Section 1.3 , Schedule of Activities ). The relevant parameters when considering the delivery of AC include 
the number, frequency, and duration of tablet -based sessions to ensure that it is appropriately matched 
to BR IGHT. The AC matches (and replicates) the duration and frequency of BRIGHT. AC was originally 
matched to BRIGHT for session duration (60 minutes) but was decreased to 30 minutes/session based on feedback during pi[INVESTIGATOR_516523]. Session topi[INVESTIGATOR_84946]: 1) HNC survivorship overview; 2) 
physical long -term HNC treatment toxicity; 3) psychosocial long -term HNC treatment toxicity, 4) health 
maintenance, and 5) financial toxicity and return -to-work. AC was pi[INVESTIGATOR_516539] s and 
refined based on their feedback to ensure its feasibility, appropriateness, and relevance. The videos are stored on the tablet and thus do not require a person for delivery; however, the study coordinator will 
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669513] TRAI NING  AND TRACKIN G 
[IP_ADDRESS]  BRIGHT  
Standardization of intervention administration is critical to ensure scientific rigor, validity, reproducibility, and achievement of study objectives . The specific duties necessary to ensure consistent and optimal 
administration of BRIGHT are detailed in the BRIGHT manual and AC standard operating procedures (SOP). All sessions of BRIGHT and AC will be audio -recorded and randomly selected sessions (20%) will be 
reviewed by a co -investigator to ensure fid elity of BRIGHT and AC in a manner that is consistent with SOP . 
If insufficient adherence to the manual is identified, appropriate remediation will occur. For BRIGHT and AC, the study coordinator will keep a tracking log capturing session duration, content  delivered, and 
technical problems with the tablet -based delivery system. Because [CONTACT_516610], the study psychologist  
helped develop BRIGHT, delivered BRIGHT in our single -arm pi[INVESTIGATOR_4251], and has experience managing 
pyscho -oncologic concerns in HNC patients, no additional specific training is planned prior to the delivery 
of BRIGHT for this trial.  
 
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLINDING  
Bias will be minimized through the randomized permuted block design. Randomization will occur at the 
individual patient level . Patients will be randomized 1:1 to BRIGHT or AC  using a permuted block 
randomization method, with randomly selected block sizes of 2 or 4. Given the impossibility of delivering BRIGHT  in a non- blinded fashion, allocation concealme nt will be non- blinded. The study statistician ( Hong 
Li, PhD) will generate and implement the randomization schema and randomization list. The study 
coordinator will implement the randomization  using the REDCap randomization module . Randomization 
errors will be handled as per the modified intention -to-treat population for the efficacy  analysis.  
   
6.4 STUDY INTERVENTION  ADHERENC E 
6.4.1  BRIGH T 
Adherence of subjects to BRIGHT study procedures are key to ensure scientific rigor, validity, reproducibility, and achievement of study objectives . Adherence will be assessed with the following 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 33 measures: 1) attendance at intervention visits; 2) duration of study visits; 3) homework completion, 4) 
psychologist rating of patient engagement and material comprehension. Att endance at all study visits are 
mandatory to remain an active participant. Adherence information will be ascertained from the BRIGHT visit note authored by [CONTACT_516584] a patient -adherence tracking log in the EMR after each 
study visit and documented in the eCase Report Form ( eCRF) after  each study visit by [CONTACT_20234].  
 
6.4.2  AC 
Adherence of subjects to AC  study procedures are key to ensure matching of the delivery format, 
frequency, duration, and schedule of the control, and thus scientific rigor, validity, reproducibility, and 
achievement of study objectives . Adherence to AC  will be assessed with the following measures: 1) 
attendance at intervention visits ; 2) duration of study visits; and 3) homework completion. Attendance at 
all study visits are mandatory to remain an active participant. Adherence information will be ascertained by [CONTACT_516585].  
 
6.5 CONCOMITANT THERAPY  
For this protocol, participants may use antidepressants and anxiolytics at the discretion of their treating 
providers. M edication  usage will be assessed at each study visit and documented in the eCRF.  
 
6.5.1  RESCUE THERAPY  
N/A  
7 STUDY INTERVENTION  DISCONTINUATION AND PARTICIPANT  
DISCONTINUATION /WITHDRAWAL  
7.1 DISCONTINUATION  OF STUDY INTERVENTI ON/EXPERIMENTAL MANIPU LATION  
At subject, PI, or study team member request.  
 When a subject discontinues from  BRIGHT or AC  but not  from the study, remaining study procedures 
will be completed as indicated by [CONTACT_516586].  If a clinically sig nificant finding is identified 
(including, but not limited to changes from baseline) after enrollment, the investigator or quali fied 
designee will determine if any change in participant management is needed. Any new clinically relevant 
finding will be reported as an a dverse e vent (AE) . 
 The data to be collected at the time of study intervention discontinuation will include the following:  
• The reason(s) for discontinuing the participant from the intervention, and methods for 
determining the need to discontinue  
• If the participant is due to complete assessments within 2 weeks of being discontinued from the 
study intervention, those assessments will be administe red at the time of discontinuation; if the next 
scheduled assessments are more than 2 weeks from the discontinuation date, the discontinued 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 34 participant will wait for the next scheduled assessment. Thereafter, the participant will be included in all 
future scheduled assessments, even though not participating in the intervention.  
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL FROM THE S TUDY  
Participants are free to withdraw from participation in the study at any time upon request. The investigators will seek to minimize participant discontinuation/withdrawal from the study (see Section 
7.3, Lost to Follow -Up) except for safety reasons.  
 An investigator or the IRB may discontinue a participa nt from  the study for the following reasons : 
• Significant study intervention non- compliance  
• Lost-to-follow up; unable to contact [CONTACT_1130]  (see Section 7.[ADDRESS_669514] to Follow -Up) 
• Any event or medical condition or situation occurs such that continued collection of follow -up  
study data would not be in the best interest of the participant  or might require an additional 
treatment that would confound the interpretation of the study  
o Subjects who are enrolled into the study and undergo a significant HNC ablative or reconstructive surgery ( defined by  a postoperative inpatient stay of at least three days) 
during the study intervention or follow -up period  
o Subjects who are enrolled in the study and develop a recurrence of their index HNC (local, regional or distant recurrence, radiologic or biopsy -proven) or metachronous second 
primary cancer (radiologic or biopsy -proven) during the study intervention or follow -up 
period  
 The rationale for having these patients discontinue the study is that a significant HN -related surgery, 
development of a HNC recurrence, or development of a second primary cancer may introduce new body image concerns, confounding the association between BRIGHT (or AC) and changes in BID . 
 The reason for participant discontinuation or withdrawal from the study will be recorded on the CRF.  
Subjects who sign the informed consent form and are randomized, regardless of whether or not they received the intervention,  will not  be replaced.  
 
7.[ADDRESS_669515] be taken if a  participant fails to return to the clinic for a required study visit:  
• The site will attempt to contact [CONTACT_2299], reschedule the missed visit within 2 weeks, counsel the participant on the importance of maintaining the assigned visit schedule and as certain 
if the participant wishes to and/or should continue in the study  
• Before a participant is deemed lost to follow -up, the investigator or designee will make every 
effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if  necessary, 
a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_9145]’s medical record or study file.  
• Should the participant continue to be unreachable, he  or she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up. 
 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 35 8 STUDY ASSESSMENTS AN D PROCEDURES  
8.1 ENDPOINT AND OTHER NON -SAFETY ASSESSMENT S 
To screen for study eligibility, the research staff will use the EMR to review clinic schedules for new or 
returning patients with a  physical  appointment in the MUSC Head and Neck Tumor Center or telemedicine 
visit with a head and neck oncology provider who are potentially eligible for the study. Clinic rosters will 
be reviewed at a minimum of once per week, or more frequently if indicated by [CONTACT_516579]. As such, screening will generally be performed within 7 days of enrollment. After a patient who is potentially eligible for the study is identified, the pat ient will be contact[CONTACT_516587] (either physically within the MUSC Head and Neck Tumor Center or during the telemedicine visit) to discuss participation in the study as described below. The study coordinator  who is screenin g the 
clinic schedule weekly will determine whether or not the potential trial participant has  consented  in EPIC 
to participate in  research studies. For patients who have consented in EPIC to participate in research 
studies, the study coordinator will recruit using existing protocols for face -face clinic -based recruitment 
and study -specific documents to describe the study. For patients who have not consented in EPIC to 
participate in research studies, the  head and neck oncology provider  for the patient will notify the patient 
of the study and introduce the study to the potential participant. Following this introduction, if the potential participant is interested in learning additional information about the trial, the study coordinator  
will recruit using exi sting standard operating procedures for  clinic- based  or telemedicine- based 
recruitment.  Patients who meet demographic and oncologic inclusion criteria will complete a screening 
BIS questionnaire; those with scores > 10 will be eligible for the study. Those with scores < 10 will not be 
eligible for the study, their BIS questionnaire will be shredded, and no personal information about the 
patient will be saved.  
 Primary Endpoint  
Change in BIS  scores . The BIS  is a validated, 10 -item patient -reported outcome measure (PROM) that 
assesses the affective, cognitive, and emotional aspects of body image due to cancer or its treatment over the prior 7 days
9. Responses include ‘not at all’, ‘a little’, ‘quite a bit’, and ‘very much’, and are scored from 
0-3, respectively. Total BIS  scores can range from 0 -30, with higher scores indicating greater body image 
dissatisfaction. The BIS  is a reliable PROM validated in oncology patients and has been widely used to 
study BID in patients with HNC44. 
 Secondary Endpoints  
Behavioral Mediator  
Change in Body Image Copi[INVESTIGATOR_503625] (BICSI) scores . The B ICSI is a 29 -item validated measure 
of the cognitive and behavioral responses to manage threats to body image10.  BICSI  contains three sub-
domains; 1) appearance fixing  (altering appearance by [CONTACT_403721], camouflaging, or correcting the perceived 
defect ), 2) avoidance  (an attempt to escape or avert stressful body -image situations), and 3) positive 
rational acceptance  (acceptance of the challenging event  and positive self -care or rational self -talk about 
one’s appearance ). Items are scored on a 4 -point Likert scale  from ‘definitely not like me’ to ‘definitely 
like me’ (0 -3). The s core s for each subscale are calculated by [CONTACT_516588]: 1) appearance fixing (0 -30), 2) avoidance (0 -24), 3) positive ratio nal 
acceptance (0 -33). For each subscale, higher scores indicate greater quantities of each conceptual domain 
(appearance fixing, avoidance, and positive rational acceptance).  Avoidance and appearance fixing are 
maladaptive means of copi[INVESTIGATOR_516540], elevated levels of BID  and 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 36 distress, and poorer  psychosocial functioning.  Positive rational acceptance is a positive means of copi[INVESTIGATOR_516541].  
 
Clinical Activity  
Change in IMAGE -HN scores: The IMAGE -HN is a psychometrically sound, 24 -item, multi -domain PROM 
consisting of 4 sub -scales and a global scale that can be used to measure key aspects of HNC -related BID  
due to HNC or its treatment45. Responses include ‘ Never’, ‘Rarely’, ‘Sometimes’, ‘Often’, ‘Always’, 
corresponding to a Likert scale of 0 -4, respectively. Total IMAGE- HN scores on the global domain (21 
questions) range from [ADDRESS_669516] -intervention that is lower than the BIS score 
at baseli ne. 
 Secondary Measures of Psychosocial Wellbeing 
Change in Shame and Stigma Scale scores . The Shame and Stigma Scale is a 20 -item, validated , 
unidimensional PROM that measures four domains (shame with appearance, stigma, regret, and 
social/speech concerns) in patients with HNC over the prior 7 days46. Responses include ‘never’, ‘ seldom’, 
‘sometimes’, ‘often’, and ‘all the time’ and are scored 0- 4, respectively. The total score is calculated by 
[CONTACT_516589] (except for 4 questions which are reverse scored ) and thus ranges from 
0-80. H igher score s reflect greater  shame and stigma  from HNC.  
 
Change in PROMIS SF v1.[ADDRESS_669517] and engagement47. Items are scored using a 5 -point Likert scale  from ‘never ’ to ‘always ’ (1-
5). The total score is calculated by [CONTACT_516590]  8-[ADDRESS_669518] more severe depressive symptoms.  
 
Change in PROMIS SF v1.0- Anxiety 8a scores . The PROMIS SF v1.0 -Anxiety 8a is a validated, 8 -item 
measure developed by [CONTACT_516591] -reported fear, worry, and hyperarousal47. Items are scored 
using a 5 -point Likert scale  from ‘never’ to ‘always’ (1-5). The total score is calculated by [CONTACT_516592]  8-[ADDRESS_669519] more severe anxiety.  
 
Change in PROMIS SF v2.0 -Satisfaction with Social Roles and  Activities 8a scores. PROMIS SF v2.0 -
Satisfaction with Social Roles and Activities 8a  is a validated, 8 -item,  measure developed by [CONTACT_516593] -reported satisfaction with performing one’s usual social roles and activities48. Items are scored 
using a 5 -point Likert sc ale from ‘ not at all ’ to ‘very much ’ (1-5). The total score is calculated by [CONTACT_516594]  8-[ADDRESS_669520] more severe anxiety.  
 
Change in PROMIS SF v2.0 -Social Isolation 8a  scores . PROMIS SF v2.0 -Social Isolation 8a is a  validated, 8 -
item,  measure developed by [CONTACT_516591] -reported perceptions of being avoided, excluded or 
unknown by [CONTACT_2312]48.  Items are scored using a 5 -point Likert s cale from ‘never’ to ‘always’ (1 -5). The total 
score is calculated by [CONTACT_516590]  8-[ADDRESS_669521] 
more severe social isolation.  
 Feasibility  
Intervention s ession duration is defined as the duration (in minutes) for each participant  
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669522] 
to the internet, video conference session, lack of video, lack of audio, insufficient tablet battery power, or 
any other technology related issues that prevents the session from otherwise functioning in a smooth and 
timely fashion.  
 
Tablet return is defined as the receipt of the study -issued tablet by [CONTACT_516595].  
 Study dropout  is defined as a participant voluntarily withdrawing from the study for whatever reason  
 Acceptability  
Timing of Intervention  will be assessed using a study -specific Likert scale measuring satisfaction with the 
timing of the intervention relative to the completion of treatment. Scores range from 0- 5 with higher 
scores representing greater satisfaction with the timing  of the intervention.  
 
Method of Delivery of the  Intervention  will be assessed using a study -specific Likert scale measuring 
satisfaction with the method of delivery of the intervention. Scores range from 0- 5 with higher scores 
representing greater satisfaction with the method of delivering the intervention.  
 
Number of Intervention Sessions  will be assessed using a study -specific Likert scale measuring satisfaction 
with the number of sessions of the interven tion. Scores range from 0- 5 with higher scores representing 
greater satisfaction with the number of intervention sessions.  
 
Session content relevance will be assessed using a study -specific Likert scale measuring satisfaction with 
the content relevance of each session . Scores range from 0-5 with higher scores representing greater 
satisfaction with the  content of the intervention.  
 
Overall satisfaction  will be assessed using a study -specific Likert scale measuring overall satisfaction with 
the intervention. Scores range from 0- 5 with higher scores representing greater satisfaction with the 
intervention.  
 
Likelihood  of Recommending the Intervention  will be assessed using a study -specific Likert scale 
measuring likelihood  of recommending the intervention. Scores range from 1 -5 with higher scores 
representing greater likelihood of recommending  the intervention.  
 
Working Alliance Inventory -Short Revised (WAI -SR) score.  The WAI -SR is 12 -item measure of working 
alliance consisting of three subscales assessing: 1) how closely client and therapi[INVESTIGATOR_516542] (goals), 2) how closely client and therapi[INVESTIGATOR_516543] (tasks), and 3) the degree of mutual trust, acce ptance, and confidence between client and therapi[INVESTIGATOR_541] (bond). Patients score on a 5 -point Likert scale 
ranging from rarely to always ( 1-5). Subscales scores for each of the subscales (goals, tasks, bond) range 
from [ADDRESS_669523] and participant.  
 Covariates  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 38 Appearance Schemas Inventory -Revised (ASI -R) Score . The ASI -R is a  psychometrically sound, 20 -item 
measure of image investmen t49. The ASI -R consists of two subdomains: S elf-Evaluative Salience (of 
Appearance) and Motivational Salience (of Appearance). Items are scored using a 5 -point Likert scale from 
‘strongly disagree’ ‘strongly agree’ (1 -5). Items 1, 4, 5, 9, 11, [ADDRESS_669524] greater levels 
of image investment.  
  
The individual’s medical chart will be used to collect information performed as part of an individual’s regular medical care are going to be used as a part of collection of trial data. As such, Health Insurance Portability and Accountability Act (HIPAA)  rules, other relevant federal or state laws, and local institutional 
requirements will be followed, as applicable. The following information is to be obtained th rough review 
of existing data:  
 
Demographics . Demographic characteristics include age, race, ethnicity, sex, marital status, living 
situation, insurance.  
 
Clinical and Oncologic Characteristics.  Clinical characteristics will include body mass index (BMI), comorbid 
medical conditions, and cancer history. Oncologic characteristics will include HNC tumor subsite, HNC tumor histology, American Joint Committee on Cancer TNM Class and overall stage groupi[INVESTIGATOR_007], type of ablative surgical, type of reconstruction, adjuvant radiation dose, adjuvant chemotherapy dose and agent, and time since completion of treatment.  
 
8.2 SAFETY ASSESSMENTS  
N/A 
 
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
8.3.1  DEFINITION OF ADVERS E EVENTS  
This trial is considered to carry a low risk to subjects (i.e. has a “no more than minimal risk” designation). As such, this protocol defines an adverse event (AE) as any undesirable sign, symptom, medical, 
psychological, social, or emotional reaction that  is definitely, probably, or possibly related to the study 
intervention.  
 
8.3.2  DEFINITION OF SERIOU S ADVERSE EVENTS  
A serious adverse event ( SAE) will be defined as any undesirable sign, symptom, or medical condition 
which is fatal, is life -threatening, requires or prolongs inpatient hospi[INVESTIGATOR_059], results in persistent or 
significant disability/incapacity, is medically significant and which the investigator regards as serious based on appropriate medical judgment that is directly due to a study intervention. An important medical 
event is any AE that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_217368], based upon appropriate medical judgment, it may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions of SAEs.  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 39  
8.3.3  CLASSIFICATION OF AN  ADVERSE EVENT  
[IP_ADDRESS]  SEVERITY OF EVENT  
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.   
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.  Of note, the term  “severe” does not necessarily  equate to “serious” . 
 
[IP_ADDRESS]  RELATIONSHIP TO STUD Y INTERVENTION /EXPERIMENTAL MANIPU LATION  
All AEs will have their relationship to study procedures, including the intervention, assessed by [CONTACT_978] 
[INVESTIGATOR_516544]. The degre e of certainty about causality will be 
graded using the categories below.  
 
• Definitely Related – There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event, including an abnormal l aboratory test 
result, occurs in a plausible time relationship to study procedures administration and cannot be explained by [CONTACT_9153]. The response to withdrawal of the study procedures should be clinically plausible. The event must be pharmacologically or phenomenologically definitive.  
• Probably Related – There is evidence to suggest a causal relationship, and the influence of other factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the study procedures, is unlikely to be attributed to concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on withdrawal.  
• Possibly Related – There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of study procedures). However, other factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it 
can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related”, as appropriate.  
 
8.3.4  TIME PERIOD AND FREQ UENCY FOR EVENT ASSESSMENT AND FOLLO W-UP 
Recording/reporting of AEs will begin after the subject signs informed consent and end after the subject 
completes the intervention and follow up period as defined in the protocol.  
 
8.3.5  ADVERSE EVENT REPORT ING  
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669525] (IRB) as soon as possible and in accordance with the reviewing IRB policy  
 
8.3.6  SERIOUS ADVERSE EVEN T REPORTING  
In consultation with the PI, a trained member of the study team will be responsible for conducting an evaluation of a SAE and shall report the results of such evaluation to the NIH and the reviewing IRB as soon as possible and in accordance with the reviewing IRB policy.  
 
8.3.7  REPORTING E VENT S TO PARTICIPANTS  
N/A  
8.3.[ADDRESS_669526]  
N/A  
8.3.9  REPORTING OF PREGNANCY  
N/A  
8.4 UNANTICIPATED PROBLE MS 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS  
This protocol uses the definition of Unanticipated Problems  (Ups) as defined by [CONTACT_31279] ( OHRP). OHRP considers unanticipated problems involving risks to participants or 
others to include, in general, any incident, experience, or outcome that meets all of the following criteria:  
 
• Unexpec ted in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol -related documents, such as the IRB -approved research protocol and 
informed consent document; and (b) the characteristics of the participant population being 
studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and  
• Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
 
8.4.2   UNANTICIPATED PROBLE MS REPORTING  
The investigator will report UP s to the reviewing IRB and to the lead PI. The UP report will include the 
following information:  
 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 41 • Protocol identifying information: protocol title and number, PI’s name, and the IRB project 
number  
• A detailed description of the event, incident, experience, or outcome  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP  
 To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
• Ups will be reported to the IRB and to the NCI in accordance with policy regarding timeliness of reporting  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s 
written reporting procedures), the supporting agency head (or designee), and the OHRP in 
accordance with policy regarding timeliness  
 
8.4.3  REPORTING UNANTICIPA TED PROBLEMS TO PART ICIPANTS  
N/A  
9 STATISTICAL CONSIDER ATIONS   
9.1 STATISTICAL HYPOTHES ES 
• Primary Endpoint:  
We hypothesize that, compared with patients who receive  the AC, patients who receive BRIGHT will  
have reduced BID as measured by [CONTACT_516596] [ADDRESS_669527] -intervention relative 
to baselin e. 
  
• Secondary Endpoint(s):  
We hypothesize that improvements in body image copi[INVESTIGATOR_172510]  (improvement  in BICSI score s from 
baseline to [ADDRESS_669528] intervention) will partially mediate a decrease in BID (reduction in B IS scores from 
baseline to [ADDRESS_669529] intervention) and this relationship will be maintained at 3 -months.  
 We hypothesize that BRIGHT will improve psychological (larger decrease in Shame and Stigma scores), 
emotional (larger decrease in PROMIS depression a nd anxiety scores), and social well- being (larger  
decrease in PROMIS social roles and social isolation scores) relative to AC at [ADDRESS_669530] -
intervention.  
 
9.2 SAMPLE SIZE  DETERMINATION  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 42 Our primary objective is to compare change in BIS scores from baseline to 1 -month intervention between 
the BRIGHT and AC arms. The primary endpoint is ∆ in Body Image Scale scores from baseline to [ADDRESS_669531] -intervention relative to 
baseline. All power and sample size calculations were performed using PASS 2008 version 08.0.13. Based 
on data from our prospective cohort  study50 and single -arm pi[INVESTIGATOR_516545], we estimate the mean  ∆ in 
Body Image Scale scores ± SD from baseline to [ADDRESS_669532] are 0. 2 ± 5.9 and 4. 6 ± 3.[ADDRESS_669533] cancer patients with BID51,52. For n=22/arm (proposed sample 
size), power exceeds 80% for mean difference in change in Body Image Scale scores of at least 3.1 (with SD as large as 4) or mean difference of at least 5.5 (with SD as large as 7) based on two -sided t -test with 
α=0.1 (Fig. 4A). Group sample size of n=22 (AC, BRIGHT) achieved 80.2% power to detect the 
standardized effect (mean difference in ∆ Body Image Scale score from baseline to 1 -month divided by 
[CONTACT_516597]=5.62)  of 0.[ADDRESS_669534] with two -sided α=0.1 ( Fig 4B). We will have 
greater than 90% power for a standardized effect size of 0.93 and greater than 80% power for a standardized effect size of 0.78. These are both considered moderate effect sizes and are feasible for continuous outcomes in the context of variables that are expected to be modulated by [CONTACT_516598]. Our power estimate is conservative given ou r proposed analysis plan using LME regression, 
which borrows strength over time and is generally more efficient than a  t-test. As such we anticipate that 
smaller effect sizes than described above will be detectable. Our selection of relaxed significance (α  = 0.1) 
with maintained power (1 – β = 0.8) is based on the desire to emphasize power over type I error at this 
early stage of development (single- site pi[INVESTIGATOR_4265]) to ensure follow -up on promising interventions to guide 
and power a subsequent larger RCT to fully evaluate the efficacy of BRIGHT as a treatment of BID in HNC 
survivors (i.e. test BRIGHT with significance level of 0.05) . We therefore consider our RCT to be 
appropriately and rigorously designed to detect a clinically meaningful reduction in BID.  
 Fig. 4. Power Calculations for (A) Mean difference in ∆  in Body Image Scale scores between baseline and [ADDRESS_669535] intervention, comparing BRIGHT and AC; (B) standardized effect, comparing ∆  in Body Image 
Scale scores between BRIGHT and AC from baseline to [ADDRESS_669536] intervention  

BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669537] 44 patients  eligible for the efficacy analysis in the modified ITT population (see Section 
9.3, Population  for Analyses ), we plan to enroll 52 patients. Our sample size is inflated by 20 % based on 
interim  accrual data. This  inflation account for study dropout and the predictable subset of patients would 
be enrolled in the study, be randomized to BRIGHT or AC , receive a portion o r all o f the intervention and 
then subsequently are withdrawn  from the study and non -evaluable  due to  a major HNC surgery or 
recurrent or second primary cancer. 
 Every effort will be made to minimize missing data and lost -to-follow -up participants. Participants will 
complete assessments at baseline, [ADDRESS_669538] three times using a variety of methods of communication (e.g. text message, phone call, email, mail, etc. ) to complete outcome measures. This method resulted in 100% instrument 
completion in our single arm pi[INVESTIGATOR_799]. In the event that missing data do occur, we will address them via standard multiple imputation procedures
53,54. As participants will be randomized to treatment, it is 
unlikely that missing data will produce biased estimates of treatment effect, as observed and unobserved covariates should theoretically be balanced across treatment groups. In general, less than 10% missing data has little impact on study power and does not induce bias regardless of the missing data mechanism
55. If missing data is greater than 10%, it will be imputed using propensity score54,56 or Markov 
Chain Monte Carlo (MCMC) methods57. When covariate information is associated with whether the 
imputed variable values are missing, we will use the propensity score method, which calculates the propensity score from modeling the distribution of the missing indicator variable based on the observed data and then applies an approximate Bayesian bootstrap imputation to each group identified by [CONTACT_516599]. Otherwise, we will use the MCMC method. The data augmentation will be applied to Bayesian inference with missing data by [CONTACT_516600] (i.e., simulating the missing values based on the observation) and step for exploring the posterior distribution based on the complete sample estimates obtained from the imputation step.  
 
9.3 POPULATIONS FOR A NALYSES  
Participants will be defined as evaluable for the primary endpoint (change in BIS from baseline to [ADDRESS_669539] -treatment) and thus included in the efficacy analytic population if they are enrolled in the study and 
randomized. However, there are two subset s of patients ( 7.2, Participant Discontinuation/Withdrawal) 
for whom the investigator may discontinue participation due to an event or medical condition or situation 
occurs such that continued collection of follow -up  study data would not be in the best in terest of the 
participant or might require an additional treatment that would confound the interpretation of the study . 
Specifically,  
1. Subjects who are enrolled into the study and undergo a significant HNC ablative or reconstructive surgery ( defined by  a postoperative inpatient stay of at least three days) during the study 
intervention or follow -up period. 
2. Subjects who are enrolled in the study and develop a recurrence of their index HNC (local, regional or distant recurrence, radiologic or biopsy -proven) o r metachronous second primary cancer 
(radiologic or biopsy -proven) during the study intervention or follow -up period.  
 We will also perform an efficacy analysis on the per -protocol analytic dataset, a subset of the ITT 
population who completed all 5 intervention (BRIGHT and AC) sessions. These patients are judged to have 
complied with the protocol sufficiently to ensure that these data would be likely to represent the effects of BRIGHT according to the underlying scientific model.  
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669540] 
intervention. Summary descriptive statistics (e.g. frequencies and percent for categorical variables, and mean, median, standard deviation, and range for continuous var iables ) will be reported . For inferential 
tests, we will use a p -value of 0.05, two -sided, and 95% confidence intervals (CIs) to assess statistical 
significance (Type I error). Covariates will be pre -specified as described below. Normality of the data will  
be assessed before underlying statistical procedures will be performed. We will evaluate variable transformations as needed to satisfy assumptions and consider transformations of variables to induce approximate normality and stabilize variance as needed. Nonparametric tests will be applied when appropriate.  
 
9.4.2  ANALYSIS OF THE PRIMARY ENDPOINT(S)  
Longitudinally measured BIS  scores will be modeled using linear mixed effects (LME) regression with the 
measures at each time point relative to baseline (denoted by ∆) as the response variable and fixed effects 
for experimental conditions (BRIGHT, AC), time ([ADDRESS_669541] intervention) and 
their interaction. Models will include subject -specific random effects to account for correlation among 
measu res obtained from the same subject over time. We will use qq -plots and histograms to investigate 
the assumption of approximate normality and consider transformations (e.g., log) as needed. We will assess the functional form of time to account for any non -linear temporal trends and consider 
transformations as needed. Comparisons of the change from baseline to each time point between conditions will be performed using model -based linear contrasts.  Data will be disaggregated by [CONTACT_654], sex, 
and race to allow for analysis of each as biological variables.  
 
9.4.3  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
For secondary endpoints related to psychological, emotional, and social well -being, graphical displays 
such as scatterplots and boxplots will be constructed to demonstrate pat terns of individual continuous 
measures and differences between baseline, [ADDRESS_669542] intervention. Summary 
descriptive statistics (statistics (e.g. frequencies and percent for categorical variables, and mean, median, 
standard deviation, and range for continuous variables ) will be reported . Longitudinal measures of 
psychological, social, and emotional well -being will be modeled using LME regression with the measures 
at each time point relative to baseline (denoted by ∆) as the response variable and fixed effects for experimental conditions (BRIGHT, AC), time ([ADDRESS_669543] intervention) and their 
interaction. Models will include subject -specific random effects to account for correlation among 
measur es obtained from the same subject over time. We will use qq -plots and histograms to investigate 
the assumption of approximate normality and consider transformations (e.g., log) as needed. We will assess the functional form of time to account for any non -linear temporal trends and consider 
transformations as needed. Comparisons of the change from baseline to each time point between 
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669544] of the 
intervention  (path c) will be partitioned 
into direct (path c’ ) and indirect effects, 
which we will test for statistical signiﬁcance ( Fig. 5). We will examine the 
direct effect of the intervention on 
change in BID ( ∆ in Body Image Scale 
score) the mediating effect of change in 
body image copi[INVESTIGATOR_172510] ( ∆ in Body 
Image Copi[INVESTIGATOR_516546]) on change in BID, and the effect of the intervention on the mediator ( ∆ in Body Image Copi[INVESTIGATOR_516521] s core ). If paths a, b,  and c  are statistically significant and c’  (the direct effect) is 
reduced compared with c  (the total effect), then partial mediation criteria are satisfied.  The significance 
of the mediating effect will be tested using robust bootstrappi[INVESTIGATOR_007]. Bootstrappi[INVESTIGATOR_516547] p values. In situations with smaller samples and non -
normal distributions, the bootstrappi[INVESTIGATOR_516548].  The confidence interval for the medi ating effect will be provided from 
the bootstrap analysis with the ‘robmed’ R package. This analysis will be repeated for change in BID at [ADDRESS_669545] interaction (moderator -
intervention -time) for age, sex and race.   
 For secondary endpoints related to the feasibility and acceptability objectives, simple frequencies will 
characterize participant satisfaction with the following aspects of the intervention: timing, method of 
delivery, number of sessions, content relevance , homework utility, attentiveness of the study 
psychologist, overall satisfaction, and likelihood to recommend BRIGHT. Descriptive statistics will be presented. Our interdisciplinary team will meet after completion of study data analyses to interpret the implications of these findings for how to refine BRIGHT based on these data in preparation for our future 
large -scale trial.  
 
9.4.4  SAFETY ANALYSES  
N/A  
9.4.5  BASELINE DESCRIPTIVE STATISTICS  
Fig. 5. Exploratory mediator analysis . Changes in body image 
copi[INVESTIGATOR_172510] (Mediator [M1]) are hypo thesized to mediate 
the effect of the intervention (independent variable [IV]) on 
changes in body image disturbance (dependent variable [DV]).  

BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 46 Baseline characteristics (e.g.,  demographics, oncologic details, behavioral characteristics) for the BRIGHT 
and AC arms will be compared and descriptive statistics calculated. Baseline differences between the two 
groups will be compared using t -tests and chi -square tests, or Wilcoxon rank sum and Fisher’s exact tests 
as appropriate.  
 
9.4.6  PLANNED INTERIM ANALYSES  
N/A  
9.4.[ADDRESS_669546] of inclusion across the lifespan, race, and s ex as biologic variables.  
 
9.4.8  TABULATION OF INDIVI DUAL PARTICIPANT DAT A 
Individual participant data will not be listed by [CONTACT_8707].  
 
9.4.9  EXPLORATORY ANALYSES  
N/A  
10 SUPPORTING DOCUMENTATION AND OPERATIONAL  CONSIDERATIONS  
10.1 REGULATORY, ETHICA L, AND S TUDY OVERSIGHT CONSIDERATIONS  
10.1.1 INFORMED CONSENT PRO CESS  
[IP_ADDRESS]  CONSENT/ASSENT AND O THER INFORMATIONAL D OCUMENTS PROVIDED TO  
PARTICIPANTS  
  
Consent forms describing in detail the study intervention, study procedures, and risks will be  provided to 
the participant (either on paper or electronically as an eConsent) and documentation of informed consent 
will be completed prior to starting the study intervention.  
 
[IP_ADDRESS]  CONSENT PROCEDURES A ND DOCUMENTATION  
We will obtain full written (either via paper -based or electronic signature) i nformed consent from patients 
enrolling in the study. Informed consent will occur via face -face discussion  in clinic or via telemedicine  
between one of the study team members designated to perform informed consent and the potential study participant . The study member will explain the elements of the informed consent form including 
purpose, methods, extent of the study, risks, benefits, and alternatives to potential participants. Participants will be asked to  read the consent form, given appropriate time to read the document on their 
own, and allowed to ask any questions prior to signing it. Consents will be written in simple, easy -to-
understand language and obtained on the day of enrollment by [CONTACT_516601] . A study team member will answer any questions about the 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 47 study and participants will be asked to sign the consent and HIPAA forms. All participants will sign 
informed consent forms before the interv iew (either via paper -based informed consent or electronic 
signature [CONTACT_516607] -based electronic informed consent) .  All participants will receive a copy of their 
informed consent and HIPAA forms for their records  (either a paper copy or an emailed copy ). The 
informed consent process will take place in a private room in the Rutledge Tower Head and Neck Cancer Clinic, in a private room in the HCC, or the location that the patient is conducting the telemedicine clinic 
visit in cases of electronic informed consent . Only the study participant will provide informed consent. 
Subjects will be allowed up to one week to decide whether to participate in the study.  Participants will 
also complete a HIPAA form at the same time using the same procedures as described a bove. All 
participants will receive a copy of their informed consent and HIPAA forms (either paper or emailed) for 
their records. Separate copi[INVESTIGATOR_516549]’s section.  
  
10.1.2 STUDY DISCONTINUATIO N AND CLOSURE  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_21224], investigator, funding agency, and regulatory authorities. If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_112578], the IRB, and sponsor/funding agency and will provide the reason(s) for the te rmination or 
suspension. Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule.  
 Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, signif icant, or unacceptable risk to participants  
• Insufficient compliance of study staff to the protocol (e.g. significant protocol violations)  
• Data that are not sufficiently complete and/or evaluable  
 The study may resume once concerns about safety, protocol compliance, and data quality are addressed, and satisfy the funding agency, sponsor, IRB, Food and Drug Administration (FDA), or other relevant regulatory or oversight bodies (OHRP, DSMB).  
 
10.1.[ADDRESS_669547] by [CONTACT_3486], their staff, 
the safety and oversight monitor(s), and the sponsor(s)  and funding agency . This confidentiality is 
extended to the data being collected as part of this study. Data that could be u sed to identify a specific 
study participant will be held in strict confidence within the research team . No personally identifiable  
information from the study  will be released to any unauthorized third party without prior written approval 
of the sponsor/funding agency . To help protect participant confidentiality, we will assign a unique study 
ID number to each subject’s information in place of his/her name [CONTACT_516608]. All hard copy and electronic files wi ll be stored appropriately using double -locked 
methods and password- protection. Only the study team member will have access to study records. 
Participant data will be collected and recorded on either a password -protected electronic data capture 
format (Res earch Electronic Data Capture; REDCap) or paper -based forms depending upon patient 
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 48 preference. For the paper collection data method, the data collection form will be labeled only with the 
participant's unique study ID number, and then stored within locked drawers in a locked office. The information on these paper forms will be transferred to a password- protected REDCap database such that 
all data will be stored in the password -protected REDCap Database. Only members of the study team will 
have access to the data. We have no plan to use laptops, jump drives, CDs/DVDs to transport data.  
All research activities will be conducted in as private a setting as possible.  
 The study monitor, other authorized representatives of the sponsor  or funding agency , representatives of 
the IRB, regulatory agencies or representatives from companies or organizations supplying  the product , 
may inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 The study participant’s contact [CONTACT_10414]. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by [CONTACT_3488], Institutional policies, or sponsor /funding agency  
requirements.  
 It is NIH policy that the results an d accomplishments of the activities that it funds should be made available 
to the public (see  https://grants.nih.gov/policy/sharing.htm ). The PI [INVESTIGATOR_516550], confidentiality, and 
security for data dissemination and reuse  (e.g., all data will be thoroughly de -identified and will not be 
traceable to a specific study participant) . Plans for archiving  and long -term preservation of the data will 
be implemented, as appropriate.  
 To further protect the privacy of study participants, the Secretary, Health and Human Services (HHS), has 
issued a Certificate of Confidentiality (CoC) to all researchers engaged in biomedical, behavioral, clinical 
or other human subjects research funded wholly or in part by [CONTACT_48160].   Recipi[INVESTIGATOR_213079] (see https://humansubjects.nih.gov/coc/index ). As set forth 
in 45 CFR Part 75.303(a)  and NIHGPS Chapter 8.3 , recipi[INVESTIGATOR_17296] -supported research covered 
by [CONTACT_72775] (e.g., policies and procedures) that provide reasonable assurance that the award is managed in compliance with Federal statutes, regulations, and the terms and conditions of award. It is the NIH policy that investigators and others who have access to research records will not disclose identifying information except when the participant co nsents or in certain instances when federal, state, or local law or regulation requires 
disclosure. NIH expects investigators to inform research participants of the protections and the limits to protections provided by a Certificate issued by [CONTACT_17355].  
 
10.1.4 FUTURE USE OF STORED  SPECIMENS AND DATA  
Data collected for this study will be analyzed and stored with the study team. After the study is completed, the de -identified, archived data will be transmitted to and stored with the study team, for use by [CONTACT_72776].  
 
10.1.5 KEY ROLES  AND STUDY GOVERNANCE  
Principal Investigator  
[INVESTIGATOR_516551] 2.0   Version 4.0 
Protocol  #[ADDRESS_669548], MSC 550  
Charleston, SC [ZIP_CODE]  
[PHONE_10759]  
[EMAIL_9863]  
 
10.1.6 SAFETY OVERSIGHT  
Safety oversight will be under the direction of a PI. Aggregate reviews will occur by [CONTACT_978] [INVESTIGATOR_516552], UPs, 
protocol violations, audit results, early withdrawals, whether the study accrual pattern warrants continuation/action, and endp oint data. Aggregate reviews will occur monthly.  
 
10.1.7 CLINICAL MONITORING  
N/A  
10.1.[ADDRESS_669549], data and biological specimen collection, documentation and completion.  
 Quality control (QC) procedures will be implemented as follows:  
 Informed consent --- Study staff will review both the documentation of the consenting process as well as a percentage of the completed consent documents.  This review will evalua te compliance with GCP, 
accuracy, and completeness.  Feedback will be provided to the study team to ensure proper consenting procedures are followed .  
 Source documents and the electronic data --- Data will be initially captured on source documents (see 
Section 10.1.9, Data Handling and Record Keepi[INVESTIGATOR_007] ) and will ultimately be entered into the study 
database.  To ensure accuracy site staff will compare a representative sample of source data against the 
database, targeting key data points in that review.  
 
Intervention Fidelity — Consistent delivery of the study interventions will be monitored throughout the 
intervention phase of the study. Procedures for ensuring fidelity of intervention delivery are described in Section 6.2.[ADDRESS_669550] access to all trial related 
sites, source data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456]/funding agency, and inspection by [CONTACT_3482].  
 
10.1.[ADDRESS_669551]  KEEPI[INVESTIGATOR_1645]   
[IP_ADDRESS]  DATA COLLECTION AND  MANAGEMENT RESPONSI BILITIES  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 50 Data collection will be the responsibility of the clinical trial staff at the site under the supervision of the 
site investigator. The investigator will be responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported. All source documents will be completed in a neat, legible manner to ensure accurate interpretation of data.   Hardcopi[INVESTIGATOR_72745]/enrolled in the study.  Data recorded in the electronic case report form (eCRF) derived from source documents will be consistent with the data recorded on the source documents.  
 Clinical data will be entered into REDCap. The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or 
inaccurate. Clinical data will be entered directly from the source documents.  
 
[IP_ADDRESS]  STUDY RECORDS RETENT ION  
In accordance with Health and Human Services regulation at 45 CFR 46.115(b), we will retain IRB records 
for at least three years. At  the end of three years, records will be boxed, labeled, and sent to central 
storage for another three years. Research records will be retained for six years to allow evaluation and repetition by [CONTACT_516602].  
 
10.1.[ADDRESS_669552] obtaining IRB approval (See 
MUSC IRB Policy HRPP 4.14).  
10.1.11 PUBLICATION AND DATA  SHARING POLICY   
This study will be conducted in accordance with the following publication and data sharing  policies and 
regulations:  
 National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the di gital archive PubMed Central  upon acceptance for 
publication.  
 This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH- Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer -reviewed 
journals.  Data from th is study may be requested from other researchers 2 years after the completion of 
the primary endpoint by [CONTACT_516603], MD , MPH, FACS .  Considerations for ensuring 
confidentiality of these shared data are described in Section 10.1.3.  
 
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669553].  
 
10.2 ADDITIONAL CONSIDERA TIONS  
N/A  
10.[ADDRESS_669554]  
IB Investigator’s Brochure  
ICH International Council on Harmonisation   
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IND Investigational New Drug Application  
IRB Institutional  Review Board  
ISM Independent Safety Monitor  
ITT Intention -To-Treat  
LSMEANS  Least -squares Means  
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669555] Operating Procedure  
THANC  Thyroid Head and Neck Cancer  
UP Unanticipated Problem  
US [LOCATION_002]  
 
  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 53 10.4 PROTOCOL  AMENDMENT  HISTORY  
 
Table 10. Protocol Amendment History  
Version  Date  Description of Change  Brief Rationale  
2.0 3/10/2020  Title  
SoA 
Endpoints: added IMAGE -HN, EORTC  
Inclusion Criteria: added cutaneous 
and salivary gland  
Sample Size: up to 48  Grammar  
Harmonize w/ eCRF  
Novel measures  
Inclusively target population  
 
Revised effect size of AC  
3.0 8/9/20  Investigator signature [CONTACT_516609], recruitment, and informed consent  Change of study team  
 
COVID -19 related changes to 
clinic workflow necessitating telemedicine recruitment and 
electronic informed consent  
4.0 10/1/[ADDRESS_669556] been described as criteria for study discontinuation  Larger than expected 
proportion of patients  meeting 
criteria for study discontinuation due to cancer recurrence/2
nd cancers  
 
Recognition that inclusion/exclusion criteria are determined at the time of 
accrual  
    
    
    
    
    
    
    
    
    
    
    
    
    
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 54  
11 REFERENCES 
1. Jansen F, Snyder CF, Leemans CR, Verdonck -de Leeuw IM. Identifying cutoff scores for the EORTC QLQ -
C30 and the head and neck cancer -specific module EORTC QLQ -H&N35 representing unmet supportive 
care needs in patients with head and neck cancer. Head Neck 2016; [ADDRESS_669557] 1:E1493 -1500.  
2. Murphy BA, Ridner S, Well s N, Dietrich M. Quality of life research in head and neck cancer: a review of the 
current state of the science. Crit Rev Oncol Hematol 2007; 62:251 -267.  
3. Fingeret MC, Vidrine DJ, Reece GP, Gillenwater AM, Gritz ER. Multidimensional analysis of body imag e 
concerns among newly diagnosed patients with oral cavity cancer. Head Neck 2010; 32:301 -309.  
4. Fingeret MC, Yuan Y, Urbauer D, Weston J, Nipomnick S, Weber R. The nature and extent of body image 
concerns among surgically treated patients with head and n eck cancer. Psychooncology 2012; 21:836- 844.  
5. Rhoten BA. Body image disturbance in adults treated for cancer - a concept analysis. J Adv Nurs 2016; 
72:1001- 1011.  
6. Teo I, Fronczyk KM, Guindani Met al. Salient body image concerns of patients with cancer undergoing head and neck reconstruction. Head Neck 2016; 38:1035 -1042.  
7. Rhoten BA, Murphy B, Ridner SH. Body image in patients with head and neck cancer: a review of the literature. Oral Oncol 2013; 49:753- 760.  
8. Fingeret MC, Teo I, Goettsch K. Body image: a critical psychosocial issue for patients with head and neck 
cancer. Curr Oncol Rep 2015; 17:422.  
9. Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. Eur J Cancer 2001; 37:189- 197.  
10. Cash TF, Santos MT, Williams EF. Copi[INVESTIGATOR_516553] -image threats and challenges: validation of the Body 
Image Copi[INVESTIGATOR_503625]. J Psychosom Res 2005; 58:190 -199.  
11. Society AC. Cancer Facts & Figures 2018. Available at: https://www.cancer.org/content/dam/cancer -
org/research/cancer -facts -and- statistics/annual -cancer -facts -and- figures/2018/cancer -facts- and- figures -
2018.pdf . Accessed February 26 2018.  
12. Cohen EE, LaMonte SJ, Erb NLet al. American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin 2016; 66:[ADDRESS_669558] PJ. P sychosocial adjustment in head and neck cancer: the 
impact of disfigurement, gender and social support. Head Neck 2003; 25:103 -112.  
14. Millsopp L, Brandom L, Humphris G, Lowe D, Stat C, Rogers S. Facial appearance after operations for oral and oropharynge al cancer: a comparison of casenotes and patient -completed questionnaire. Br J Oral 
Maxillofac Surg 2006; 44:358- 363.  
15. Rhoten BA, Deng J, Dietrich MS, Murphy B, Ridner SH. Body image and depressive symptoms in patients with head and neck cancer: an important relationship. Support Care Cancer 2014; 22:[ADDRESS_669559] H. Intimacy and relationship processes in couples' psychosocial adaptation to cancer. 
Cancer 2008; 112:2541- 2555.  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 55 17. Osazuwa- Peters N, Simpson MC, Zhao Let al. Suicide risk among cancer survivors: Head and neck versus 
other cancers. Cancer 2018; 124:4072- 4079.  
18. Huang S, Liu HE. Effectiveness of cosmetic rehabilitation on the body image of oral cancer patients in 
Taiwan. Support Care Cancer 2008; 16:981- 986.  
19. Chen SC, Huang BS, Lin CYet al. Psychosocial effects of a skin camouflage program in female survivors with 
head and neck cancer: A randomized controlled trial. Psychooncology 2017; 26:1376 -1383.  
20. Giuliani M, McQuestion M, Jones Jet al. Prevalence and nature of survivo rship needs in patients with head 
and neck cancer. Head Neck 2016; 38:1097- 1103.  
21. Jarry JL, Ip K. The effectiveness of stand -alone cognitive -behavioural therapy for body image: a meta-
analysis. Body Image 2005; 2:317- 331.  
22. Jarry JL, Berardi K. Charac teristics and effectiveness of stand -alone body image treatments: a review of 
the empi[INVESTIGATOR_20661]. Body Image 2004; 1:319 -333.  
23. Fingeret MC, Teo I, Epner DE. Managing body image difficulties of adult cancer patients: lessons from available research . Cancer 2014; 120:633- 641.  
24. Przezdziecki A, Sherman KA, Baillie A, Taylor A, Foley E, Stalgis -Bilinski K. My changed body: breast cancer, 
body image, distress and self -compassion. Psychooncology 2013; 22:1872- 1879.  
25. Semple C, Parahoo K, Norman A, Mc Caughan E, Humphris G, Mills M. Psychosocial interventions for 
patients with head and neck cancer. Cochrane Database Syst Rev 2013:CD009441.  
26. Eldredge L, Markham C, Ruiter R, Fernandez ME, Kok G, Parcel G. Planning Health Promotion 
Interventions: An Intervention Mappi[INVESTIGATOR_187347]. San Francisco, CA: Jossey -Bass, 2016.  
27. Ellis MA, Sterba KR, Day TAet al. Body Image Disturbance In Surgically -Treated Head and Neck Cancer 
Patients: A Patient -Centered Approach. Otolaryngol Head Neck Surg Accepted.  
28. van Be ugen S, Ferwerda M, Hoeve Det al. Internet -based cognitive behavioral therapy for patients with 
chronic somatic conditions: a meta- analytic review. J Med Internet Res 2014; 16:e88.  
29. David JM, Ho AS, Luu Met al. Treatment at high -volume facilities and ac ademic centers is independently 
associated with improved survival in patients with locally advanced head and neck cancer. Cancer 2017; 123:3933- 3942.  
30. Graboyes EM, Ellis MA, Li Het al. Racial and Ethnic Disparities in Travel for Head and Neck Cancer 
Treatment and the Impact of Travel Distance on Survival. Cancer 2018; 124:3181 -3191.  
31. Implementing Cancer Survivorship Care Planning. Washington, DC: National Academies Press, 2007.  
32. Burris JL, Andrykowski M. Disparities in mental health between rural and nonrural cancer survivors: a 
preliminary study. Psychooncology 2010; 19:637- 645.  
33. Allison PJ, Edgar L, Nicolau B, Archer J, Black M, Hier M. Results of a feasibility study for a psycho -
educational intervention in head and neck cancer. Psychooncology 2004; 13:482- 485.  
34. Budhrani -Shani P, Chau NG, Berry DL. Psychosocial distress and the preferred method of delivery of mind -
body interventions among patients with head -and-neck cancer. Patient Relat Outcome Meas 2018; 9:129 -
136.  
BRIGHT 2.0   Version 4.0 
Protocol  #103191   1 October 2021 
Based on the NIH Protocol Template for Behavioral and Social Sciences Research  
 56 35. Wootton R, Bahaadinbe igy K, Hailey D. Estimating travel reduction associated with the use of 
telemedicine by [CONTACT_498147]: proposal for quantitative synthesis in a systematic 
review. BMC Health Serv Res 2011; 11:185.  
36. Doolittle GC, Spaulding AO. Providing Access to Oncology Care for Rural Patients via Telemedicine. J Oncol 
Pract 2006; 2:228- 230.  
37. Agnisarman SO, Chalil Madathil K, Smith K, Ashok A, Welch B, McElligott JT. Lessons learned from the 
usability assessment of home- based telemedicine systems. Appl Ergon 2017; 58:424- 434.  
38. Andersson G, Cuijpers P, Carlbring P, Riper H, Hedman E. Guided Internet -based vs. face -to-face cognitive 
behavior therapy for psychiatric and somatic disorders: a systematic review and meta- analysis. World 
Psychia try 2014; 13:288- 295.  
39. Graboyes EM, Maurer S, Park Yet al. Evaluation of a Novel Telemedicine -Based Intervention to Manage 
Body Image Disturbance in Head and Neck Cancer Survivors. Psychooncology 2020.  
40. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sarg ent D. Randomized phase II designs. Clin Cancer Res 2009; 
15:1883- 1890.  
41. Vickers AJ, Ballen V, Scher HI. Setting the bar in phase II trials: the use of historical data for determining 
"go/no go" decision for definitive phase III testing. Clin Cancer Res  2007; 13:972- 976.  
42. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. 
Eur J Cancer 2009; 45:275- 280.  
43. Graboyes EM, Hill EG, Marsh CH, Maurer S, Day TA, Sterba KR. Body Image Disturbance in Surg ically -
Treated Head and Neck Cancer Patients: A Prospective Cohort Pi[INVESTIGATOR_16116]. Otolaryngol Head Neck Surg Accepted.  
44. Ellis MA, Sterba KR, Brennan EAet al. A Systematic Review of Patient -Reported Outcome Measures 
Assessing Body Image Disturbance in Patients with Head and Neck Cancer. Otolaryngol Head Neck Surg 2019; 160:941- 954.  
45. Ellis MA, Sterba KR, Day TAet al. Body Image Disturbance in Surgically Treated Head and Neck Cancer Patients: A Patient -Centered Approach. Otolaryngol Head Neck Surg 2019; 16 1:278- 287.  
46. Kissane DW, Patel SG, Baser REet al. Preliminary evaluation of the reliability and validity of the Shame and 
Stigma Scale in head and neck cancer. Head Neck 2013; 35:172 -183.  
47. Pi[INVESTIGATOR_5544], Choi SW, Reise SPet al. Item banks for measuring emotional distress from the Patient -
Reported Outcomes Measurement Information System (PROMIS(R)): depression, anxiety, and anger. Assessment 2011; 18:263- 283.  
48. Hahn EA, DeWalt DA, Bode RKet al. New English and Spanish social health measures will facilit ate 
evaluating health determinants. Health Psychol 2014; 33:490 -499.  
49. Cash TF, Melnyk SE, Hrabosky JI. The assessment of body image investment: an extensive revision of the appearance schemas inventory. Int J Eat Disord 2004; 35:305 -316.  
50. Graboyes EM , Hill EG, Marsh CH, Maurer S, Day TA, Sterba KR. Body Image Disturbance in Surgically 
Treated Head and Neck Cancer Patients: A Prospective Cohort Pi[INVESTIGATOR_16116]. Otolaryngol Head Neck Surg 2019; 161:105- 110.  
BRIGHT 2.0   Version 4.0 
Protocol  #[ADDRESS_669560] 
Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized 
Controlled Trial. J Clin Oncol 2018; 36:1930- 1940.  
52. Esplen MJ, Wong J, Warner E, Toner B. Restoring Body Image After Cancer (ReBIC): Results of a 
Randomized Controlled Trial. J Clin Oncol 2018; 36:[ADDRESS_669561] J, Rubin DB. Miscellanea. Small- sample degrees of freedom with multiple imputation. Biometrika 
1999; 86:948- 955.  
54. Rubin DB. Multiple imputation for nonresponse in surveys. John Wiley & Sons, 2004.  
55. Roderick JAL. A Test of Missing Completely at Random for Multivariate Data with Missing Values. Journal of the American Statistical Association 1998; 83:1198- 1202.  
56. Lavori PW, Dawson R, She ra D. A multiple imputation strategy for clinical trials with truncation of patient 
data. Stat Med 1995; 14:1913- 1925.  
57. Schafer JL. Analysis of incomplete multivariate data. Boca Raton, FL: Chapman & Hall/CRC, 1997.  
 